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REGULATION OF ANTIGENIC VARIATION IN TRYPANOSOMA BRUCEI 
IMAAN A. BENMERZOUGA 
 
ABSTRACT 
 
Trypanosoma brucei is a protozoan parasite that causes sleeping sickness in 
humans and nagana in cattle. When inside the mammalian host, T. brucei cells stay in 
extracellular spaces and regularly switch their surface antigen, Variant Surface 
Glycoprotein (VSG), to escape the host’s immune responses. To ensure the effectiveness 
of VSG switching, T. brucei expresses a single type of VSG at any time exclusively from 
one of 20 identical VSG expression sites located next to the telomere. Monoallelic 
expression of VSG and VSG switching are important for T. brucei’s pathogenesis. Our 
major goal is to understand the mechanisms of antigenic variation regulation.  
Binding of the Origin Recognition Complex (ORC) to replication origins is 
essential for initiation of DNA replication, but ORC has non-essential functions outside 
of DNA replication including gene silencing and telomere maintenance. An Orc1/Cdc6 
homolog has been identified in T. brucei, but its function in gene silencing has not been 
investigated. In this study, we show that depletion of TbORC1 resulted in derepression of 
ES-linked silent VSGs in both mammalian-infectious bloodstream and insect procyclic 
forms. In addition, TbORC1 associates with telomere repeats but independently of known 
T. brucei telomere proteins, TbRAP1 and TbTRF. We conclude that TbORC1 is required 
to control telomere linked VSG gene silencing (Mol. Microbiol. 87(1): 196-210).  
Telomeres are nucleoprotein complexes located at ends of linear chromosomes 
and are essential for maintaining genome integrity. We have identified T. brucei TRF as a 
duplex telomere DNA binding factor. Nevertheless, the function of TbTRF in antigenic 
! vii 
variation has not been studied.  In this study, we solve the NMR structure of the TbTRF 
MYB domain and we determined point mutations that weaken or abolish the DNA 
binding activity of TbTRF in vitro. We successfully targeted these point mutations in vivo 
and studied the role of TbTRF DNA binding mutants in antigenic variation. Finally, we 
found that the modified J residue (beta-D-glucosyl-hydroxymethyluracil) found in 
telomeres does not influence the association of TbTRF with the telomere in-vitro. 
Tel2 was first identified in yeast and has been shown to be essential for telomere 
length maintenance. Subsequently, Tel2 homologues have been identified in different 
organisms including worm, human, and T. brucei. Recent studies report that mammalian 
Tel2 regulates the stability of PI3-K related kinases (PIKK). TbTEL2 was identified 
through an in silico approach. Our preliminary data suggest that TbTEL2 is important for 
telomere end-protection, possibly regulates PI3K-Related protein kinases stability, and 
appears to affect VSG switching. 
These studies will provide additional insights into T. brucei’s pathogenesis, and 
possibly lead to the identification of putative targets for anti-parasitic therapies, not only 
against T. brucei but also other parasites that utilize antigenic variation to evade the host 
immune responses.  !!!!
 !!
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CHAPTER I 
INTRODUCTION 
Summary 
Trypanosoma brucei is the causative agent of African sleeping sickness or Human 
African Trypanomoasis (HAT), which is fatal if left untreated. Many drugs have been 
developed to treat HAT, but most of the drugs are toxic to patients. This makes the 
understanding of the molecular pathogenesis of T. brucei indispensable for the 
development of safer treatments. T. brucei manages to escape host immune responses via 
antigenic variation. T. brucei replicates in the bloodstream of its mammalian host and is 
continuously exposed to the host immune system. Therefore, T. brucei expresses a 
protective surface coat. This surface coat is known as Variant Surface Glycoprotein 
(VSG). There are more than 1000 VSG genes and pseduogenes in T. brucei’s genome. 
This allows T. brucei to maximize the efficiency of escaping the host immune responses. 
In order to achieve this, T. brucei expresses one VSG at a time, a phenomenon known as 
monoallelic VSG expression. In addition, T. brucei regularly switches its expressed VSG 
via transcription or recombination based pathways. It is important to note that the VSG 
gene is exclusively expressed from an expression site located at the sub-telomere. Many 
factors that regulate antigenic variation have been described including telomeric proteins. 
Nevertheless, antigenic variation is a complex process and not all factors that regulate 
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antigenic variation have been identified. My thesis goal was to study the regulation of 
antigenic variation by proteins that associate with telomeres. These studies will possibly 
lead to the identification of putative targets for trypanocidal therapies.  
 In this chapter, I will introduce you to Trypanosoma brucei, its life cycle, the 
class Kinetoplastida, African sleeping sickness and its current available therapies. I will 
also introduce you to the concept of antigenic variation and how T. brucei utilizes 
antigenic variation. Also, I will introduce you to the factors that regulate antigenic 
variation and the modified thymine residue known as J-base or base J found in 
kinetoplastids. Finally, I will introduce you to telomeres and T. brucei’s telomere 
complex.  
 
Trypanosoma brucei  
 
Trypanosoma brucei is a unicellular protozoan parasite that belongs to the class 
Kinetooplastida and the order Trypanosomatida. T. brucei is a heteroxenous organism, 
meaning it needs more than one host to complete its life cycle. There are three sub-
species of Trypanosoma brucei: T. brucei. brucei, T. brucei. gambiense and T. brucei. 
rhodesiense. All three sub-species are morphologically indistinguishable. Nevertheless, 
there are some variations among these sub-species including the host they infect, the 
severity of the infection and their epidemiology. Both T. b. gambiense and T. b. 
rhodesiense are the etiological agents of African sleeping sickness in humans, where T. b. 
brucei is the parasite of native antelopes, live stock and other African ruminants causing 
animal trypanosomiasis or nagana (Roberts et al. 2009). All three sub-species utilize an 
insect vector from Glossina spp. T. b. gambiense causes a chronic form of sleeping 
sickness while T. b. rhodesiense causes an acute form of the disease. Finally, T. b. 
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gambiense is a major problem in Central and West Africa and T. b. rhodesiense is a 
burden to Eastern and Southern Africa (Roberts et al. 2009).  
T. b. brucei does not infect human because it is sensitive to the normal human 
serum, which contains the trypanosome lytic factor (TLF). There are two mechanisms 
whereby resistance evolved against TLF. In T. b. rhodesiense the expression of a serum 
resistance associated protein (SRA) neutralizes TLF by binding to it (De Greef C et al. 
1989). However, T. b. gambiense lacks SRA and instead the TLF receptor in T. b. 
gambiense has a greatly reduced affinity to TLF (Kieft et al. 2010), but other mechanisms 
of resistance remain unknown, since there is a group in T. b. gambiense that lacks SRA, 
uptakes the TLF and yet is resistant to the normal human serum (De Jesus E et al. 2013).  
These differences illustrate the diversity of T. brucei sub-species (Roberts et al. 2009). 
 
Trypanosoma brucei Life Cycle 
T. brucei undergoes complex changes during its life cycle, as means of surviving 
in the two hosts: insect and human (Figure: 1-1). Throughout its life cycle, T. brucei 
expresses surface glycoproteins. It all starts from a blood meal, where T. brucei is carried 
to the midgut of the tsetse fly (Glossina spp). It resides in the posterior section of the 
midgut and rapidly multiplies for approximately 10 days!(Roberts et al. 2009). While in 
the midgut of the tsetse fly, T. brucei expresses procyclin as a surface molecule. 
Procyclin is a protease resistant surface molecule. It protects T. brucei from hydrolytic 
enzymes that are present in the tsetse’s gut (Gruszynski et al. 2006). When T. brucei is 
ready to be transmitted to the mammalian host, it migrates through the digestive and 
respiratory tract of the tsetse fly, eventually reaching the salivary glands of the tsetse fly. 
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In the salivary glands, T. brucei prepares for infection and differentiates into the 
metacyclic form (a non-dividing infectious form of T. brucei), which is small, stumpy 
and has no flagellum. At this stage, while still in the insect, T. brucei initiates the 
expression of Variant Surface Glycoprotein (VSG), while the abundant procyclins are no 
longer expressed! (Graham and Barry 1995). Metacyclic VSGs (mVSGs) are different 
from bloodstream form VSGs (B-ES), as they only constitute 1-2% of the VSG repertoire 
(Graham and Barry 1995). They are also monocistronically transcribed (Alarcon et al. 
1994). The expression site is structurally different than the bloodstream expression site 
and the promoter of mVSG is only activated during metacyclic stage (Graham and Barry 
1995). Upon a blood meal, the tsetse fly inoculates the mammalian victim with infectious 
metacyclic trypanosomes.  
Metacyclic trypanosomes transform to an infectious dividing form known as 
bloodstream form and reside in the bloodstream, lymph nodes, spleen and cerebrospinal 
fluid of its mammalian host. A single bite from a tsetse fly inoculates the host with up to 
several thousands of metacyclic trypanosomes (Roberts et al. 2009). Depending on the 
sub-species, T. brucei may or may not reach the central nervous system (CNS). In acute 
infections by T. b. rhodesiense, trypanosomes invade almost all organs, which results in a 
rapid course towards death. In chronic infections via T. b. gambiense, trypanosomes 
invade the central nervous system causing the symptoms of sleeping sickness disease. 
Regardless of the sub-species, during this stage, T. brucei expresses bloodstream VSGs, 
where only one VSG is expressed at any time. There are more than 1000 VSGs that have 
been identified in T. brucei’s genome, providing T. brucei with a huge repertoire to 
exhaust the host immune responses. Bloodstream VSGs like mVSGs are expressed from 
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sub-telomeric loci. When T. brucei reaches its terminal non-dividing stage, a blood meal 
by the tsetse fly from the mammalian host, once again, recapitulates the whole life cycle 
(Figure: 1-1a).  
 
Class Kinetoplastida 
Class Kinetoplastida harbors single cell organisms that parasitize many 
eukaryotes. In this class, there are three major parasites of the human, Leshmania spp that 
cause Leshmaniasis, Trypansoma cruzi that causes American trypanosomiasis or Chagas 
disease and finally, Trypanosoma brucei, the causative agent of African sleeping sickness 
in human. The majority of species that are under this class requires an arthropod or an 
insect vector to infect its mammalian host. This class was named after the “Kinetoplast”, 
a single mitochondrial DNA containing body in addition to the nucleus. The kinetoplast 
is utilized to determine the stage of the parasite. Typically a species belonging to the class 
kinetoplastida should have the following stages: amastigote, promastigote, epimastigote 
and finally trypomastigote. An amastigote is a round form of the species with very short 
flagellum. This stage is found in Trypanosoma cruzi and Leshmania spp. These parasites 
live in the intercellular spaces of the host. In the promastigote stage, the kinetoplast is 
found at the anterior of the parasite’s body. The epimastigote stage is similar to the 
promastigote stage in terms of the location of the kinetoplast, but during this stage a 
prominent undulating membrane appears. Upon full maturation, the parasite is in a 
trypomastigoe stage where the kinetoplast is found posterior to the nucleus!(Roberts et al. 
2009). In addition, the kinetoplast is used to determine the phase of the cell cycle. In T. 
brucei replication of the kinetoplast and the division of the kinetoplast precedes the 
! 6 
nuclear division. Therefore G1, S and G2 phases can be determined through cytological 
analysis for the location of the nucleus and kinetoplast as well as the DNA content 
(Sherwin and Gull 1989).  
 
African Sleeping Sickness  
 
Human African Trypanosomoasis (HAT) or African sleeping sickness is 
considered one of the most neglected tropical diseases (Stephens et al. 2012). Sub-
Saharan Africa harbors the main habitat for tsetse flies, reporting the majority of the 
cases to the World Health Organization (WHO). Recent epidemiological studies have 
revealed a substantial decrease in the number of declared cases to WHO to approximately 
10,000 cases a year or less (Bisser and Courtioux 2012). However, this number is largely 
an underestimation due to the lack of advanced molecular tools to diagnose 
trypanosomoasis at its early stages (Welburn and Maudlin 2012). In addition, during the 
early 1960s, the HAT disease was no longer considered a public health problem (Garcia 
et al. 2006). However, it returned to alarming levels in the 1990s (Garcia et al. 2006). 
Moreover, there are reportedly non-endemic cases that are a result from military 
assignments, tourists or immigrants that resided in sub-Saharan Africa. The non-endemic 
cases may not show the exact symptoms shown by the endemic cases due to their genetic 
differences, retarding their diagnosis and treatments (Blum et al. 2012). 
Depending on the T. brucei sub-species, the average survival can range from 3 
years to several weeks. The disease course is divided into two stages. The first stage is 
exemplified by fever, headache, swollen lymphnodes (lymphadenopathy), enlargement of 
the spleen and liver (hepato-splenomegaly). During the second stage, where T. brucei has 
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infiltrated the CNS and crossed the blood brain barrier (BBB), neuro-psychological 
disorders are prominent such as Parkinson like movements, paralysis of the extremities 
and speech disorders, in addition to disruption of the circadian rhythm or “sleeping 
disorder” hence the name “sleeping sickness” (Blum et al. 2012). Not all clinical 
presentations of HAT are comparable, making early diagnosis a great challenge. Host 
genetics, co-infections genetic background of the parasite and host-parasite interactions 
are major attributions to this diversity (Morrison 2011). 
Treatment of HAT varies with the stage of the disease, where the later stage 
utilizes drugs with greater toxicity. The first stage drugs are Pentamidine for gambiense 
or Suramin for rhodesiense (Simarro et al. 2008). The Pentamidine mechanism of action 
is not completely clear. It is hypothesized that it interferes with T. brucei’s nucleic acid 
metabolism.  Pentamidine is an aromatic diamidine having various toxic side effects. In 
addition, it is not effective against the second stage of the Gambian HAT, making it the 
least effective chemotherapeutic treatment available (Bacchi 2009). On the other hand, 
Suramin is a sulfonated naphthylamine (Bacchi 2009). It has been shown to inhibit 
several enzymes including thymidine kinase and enzymes in the glycolytic pathway. 
However, Suramin does not cross the BBB, making it a less effective drug against HAT 
(Wang 1995).!
The second stage disease drugs are Eflornithine or Melarsoprol. Eflornithine or 
difluoromethylornithine (DFMO) is less toxic and only effective in the Gambian HAT. 
DFMO is an irreversible inhibitor of ornithine decarboxylase (ODC). ODC is the rate- 
limiting and the initial enzyme in the polyamine synthetic pathway (Bacchi 2009). 
However, DFMO is not trypanocidal and depends on the immune system to eliminate 
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non-dividing trypanosomes. Melarsoprol is the most toxic drug available to treat HAT. It 
is arsenical and targets the S-H group found in many enzymes. It also, interferes with 
ATP production. Death of trypanosomes occurs as a result of diminished energy (Bacchi 
2009). Melarsoprol is insoluble in water and only soluble in organic solutions such as 
propylene glycol. In addition, it must be administered intravenously causing damage to 
the veins. Death occurs within 48 hours of melarsoprol treatment due to its adverse side 
effects such as pulmonary edema and encephalopathy (Bacchi 2009). The high failure 
rate of melarsoprol treatment makes it a less effective treatment available for HAT 
(Chappuis 2007).  
Finally, most recently a combination of Nifurtimox and Eflornithine has been 
introduced in the clinics as a cost-effective treatment for HAT (Simarro et al. 2008). 
Nifurtimox is a registered drug to treat American sleeping sickness disease. Clinical trials 
for this combination showed >94% cure rate (Chappuis 2007). Currently, this 
combination therapy is the best treatment option available for Gambian HAT (Alirol et al. 
2013). Careful follow up of all cases will deduce whether this combination therapy 
results in any relapse, since resistance to mono-therapy has emerged (Alirol et al. 2013).  
All drugs require special administration and special training. Many of the drugs 
are toxic and are not effective for both stages. In addition, resistance has emerged against 
several available drugs (Alirol et al. 2013). Moreover, recent reports have shown that T. 
b. gambinese crosses the BBB five hours post infection complicating the available 
courses of treatment (Frever et al. 2012). Therefore, it is crucial to discover trypanocidal 
drugs that will be effective to kill the trypanosome regardless of disease stage. In 
addition, vector control must be used against Glossina spp that causes HAT (Simarro et 
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al. 2008). Active research is on going to find bait-based traps that will help control the 
Glossina spp causing HAT. In addition finding safer and more effective remedies for 
HAT is urgently needed. This requires the identification of improved drug targets by the 
identification of essential genes in T. brucei, that if targeted will not affect the host. !
 
Genome of T. brucei 
 
The genome of Trypanosoma brucei is 26 megabase in size predicting 9068 genes 
(Berriman et al. 2005). The 26 Mb genome consists of 11 diploid large chromosomes 
known as Mega Base Chromosomes (MBCs) ranging in size from 1-5.2 Mb!(Melville et 
al. 1998), several Intermediate Chromosomes (ICs) ranging in size 200-900 Mb, and 
finally minichromosomes (MCs) that range in size between 50- 150 kb (El-Sayed et al. 
2000). The terminal repeats of MBCs, ICs and MCs are of TTAGGG sequence. Some of 
the telomeres of MBCs and ICs are linked to expression sites for genes encoding Variant 
Surface Glycoprotien (VSG) (El-Sayed et al. 2000). MCs carry silent VSG gene copies 
and are mainly thought to contribute to the T. brucei genome as a reservoir of additional 
VSGs (Alsford et al. 2001). Unlike MBCs and ICs, none of the MCs are linked to 
expression sites (El-Sayed et al. 2000). MCs replicate and segregate faithfully over 
several years of growth (Alsford et al. 2001). There are 1700 T. brucei specific genes and 
~ 900 pseudogenes (Berriman et al. 2005), most VSG genes in the genome are 
pseudogenes (Berriman et al. 2005; Rudenko 2011,), and little is known to how 
pseudogenes are recombined to produce functional VSGs (Rudenko 2011).  
Variant Surface Glycoprotein (VSG) 
VSG is a dense layer of a single species of glycoprotein (Borst and Rudenko 
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1994). There are approximately 107 identical molecules of VSG on the surface of the T. 
brucei. These VSGs are relatively 60 kDa in molecular mass (Metcalf et al. 1987). The 
N-terminus of VSG is hydrophilic, where the C-terminus is hydrophobic (Carrington et 
al. 1991). The N-terminus of VSG extends outwards facing the extracellular space, where 
the hydrophobic pocket is tethered to the plasma membrane through a GPI 
(glycosylphosphatidylinositol) anchor (Dubois et al. 2005). This rod-like architecture 
allows the VSGs to be tightly packed creating a dense layer on the surface of the 
trypanosome (Figure: 1-1b).  
At the sequence level, the N-terminus of VSG is variable among all VSGs, while 
the C-terminus is quite conserved (Carrington et al. 1991). Despite the differences at the 
sequence level for different VSGs, high-resolution X-ray crystallography structures 
revealed a conserved secondary and tertiary structure (Metcalf et al. 1987), possibly to 
pack all VSGs in a similar manner prior to becoming a surface coat (Dubois et al. 2005). 
VSGs are susceptible to cleavage via proteases such as a zinc metalloprotease activity 
(MSP-B) and GPI-specific phospholipase (GPI-PLC) to shed a pre-existing VSG 
(Gruszynski et al. 2006). It takes approximately 48 hours for a pre-existing VSG to be 
completely eliminated and replaced with a new VSG coat (Dubois et al. 2005). 
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Figure 1-1:  An introduction to Trypanosoma brucei . (A) Life cycle of T. brucei (Lee et 
al. 2007). (B) EM of a cross section of T. brucei cell showing VSG molecules. Image was 
obtained from tryps.rockefeller.edu. (C) Architecture of a VSG expression site.  
 
Architecture of VSG-ES 
T. brucei’s VSG-ES is composed of the VSG at a sub-telomeric position, a 70 bp  
upstream repeat sequence and several expression site associated genes or (ESAGs), 
which are located several kbs upstream of VSG gene (Alexandre et al. 1988). ESAGs are 
believed to provide genomic redundancy or polymorphism to facilitate homologous 
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recombination necessary for host adaptation (Berriman et al. 2002). The promoter is 
located 40-60 kb upstream of the VSG gene (Pays et al. 1989). Transcription of VSG-ES 
is carried out by RNA Pol-I; the polymerase resistant to alpha amanitin (Pays et al. 1989). 
 
Antigenic Variation 
Many parasites and microbial pathogens evade the immune responses via 
antigenic variation, a phenomenon that is common among parasites or microbes that 
express a surface molecule (Li 2012). In antigenic variation, T. brucei expresses a single 
surface molecule at anytime, and regularly switches the expressed surface molecule 
(Figure 1-2a) to escape the host immune responses (Namangala 2011). In order to 
achieve antigenic variation, T. brucei must meet three criteria: First, it must harbor 
antigenically distinct surface antigens that are encoded from the same gene family. 
Second, a mechanism whereby T. brucei cells express one surface molecule at a time and 
finally, a mechanism that enables T. brucei to regularly switch its surface antigen 
(Stockdale et al. 2008). VSG genes and psudeogenes serve as a huge repertoire for T. 
brucei, conferring to the first requirement. VSG array can be found at subtelomeric loci of 
MBCs, linked to expression sites of MBCs or ICs and at subtelomeres of MCs (Figure: 1-
2b). In addition, T. brucei expresses one VSG at anytime through monoallelic expression, 
where all the expression sites are silent except for the expression site of the active VSG 
(Figure: 1-2c). Finally, T. brucei switches its expressed surface antigen through 
transcription or recombination based pathways as illustrated in (Figure: 1-2d). During 
VSG switching, T. brucei can undergo an in-situ switch by turning off the promoter of the 
originally active ES and turning on the promoter of the originally silent ES.  
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Figure 1-2: Antigenic Variation. (A) Antigenic variation in Trypanosoma brucei. (B) 
VSG genes repertoire. (C) Monoallelic expression. (D) VSG switching: Possible 
mechanisms.  
 
It can also undergo a Gene Conversion event or a Telomere Exchange. In Gene 
Conversion, the original VSG is lost in the genome. In addition, either a whole expression 
site is duplicated and inserted into the originally active ES or only the VSG is duplicated 
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and inserted into the originally active ES.  Finally, in a Telomere Exchange, the VSG in 
the originally silent ES is crossed-over with the VSG in the originally active ES. VSG 
switching and monoallelic expression are tightly regulated in T. brucei, making antigenic 
variation one of the most sophisticated methods developed by this unicellular parasite to 
evade the host immune system (Taylor and Rudenko 2006). 
 
VSG Regulation. 
Several factors have been reported to regulate VSG switching or monoallelic 
expression or both (reviewed by Li 2012). Recent studies have shown that VSG can be 
regulated by 1) Chromatin remodeling factors (Janzen et al. 2006; Hughes et al. 2007, 
Wang et al. 2010; Denninger et al. 2010; Povelones et al. 2012) and nucleosome 
packaging (Rudenko 2010; Stanne and Rudenko 2010; Figueiredo and Cross 2010), 2) 
Transcription elongation and transcription factors (Vanhamme et al. 2000; Narayanan et 
al. 2011), 3) Telomere proteins (Yang et al. 2009) and telomere length (Hovel-Miner et 
al. 2012), 4) DNA recombination (McCulloch and Barry 1999; Proudfoot and McCulloch 
2005; Hartley and McCulloch 2008;  Kim and Cross 2010; Kim and Cross 2011) and 5) 
DNA replication ( Tiengwe et al. 2012a; Benmerzouga et al. 2013).   
Chromatin remodeling was shown to play a crucial role in the regulation of VSG 
expression at the promoter level. Several studies reported chromatin-remodeling factors 
influencing the expression of silent VSGs at the promoter, where transcription at the 
promoter increases upon the depletion of this factor but does not reach the VSG and 
hence no increase in VSG expression is observed. TbDot1b, a histone 3 lysine 76 
methyltransferase in T. brucei, regulates the expression of silent VSGs. The deletion of 
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TbDot1b resulted in a 10-fold increase in transcription of silent B-ES (Janzen et al. 
2006). ISWI, a novel member of the chromatin remodeling family SWI/SNF2-related 
was reported in T. brucei. Depletion of TbISWI led to the derepression at the ES 
promoter by 30-60 fold in BF cells and 10-17 fold in PF cells (Hughes et al. 2007). 
Another study by (Denninger et al. 2010) reported that the chromatin remodeling 
complex, FACT subunit- TbSpt16- was important for the silencing at the ES promoter in 
both life stages. Finally, the depletion of the histone deacetylase (DAC3) showed 
derepression at the promoter, a similar observation that was observed for TbISWI (Wang 
et al. 2010). Although there are Sir2 related proteins in T. brucei, which are NAD-
dependent histone deacetylases, none of the TbSir2rps influence VSG silencing or 
switching (Alsford et al. 2007). It is evident from these studies that chromatin remodeling 
plays a regulatory role in VSG silencing and not all known chromatin remodeling factors 
influence VSG silencing. Finally, depletion of Histone 1 (H1) resulted in 6-8 fold of 
derepression at the promoter of a silent VSG in BF cells and a 3 fold derepression in PF 
cells (Povelones et al. 2012). In addition to chromatin remodeling factors, nucleosome 
packaging was shown to be different between active and silent B-ES (Stanne and 
Rudenko 2010), where the active ES is depleted of nucleosomes.  
A second factor regulating VSG expression is transcription. Early studies showed 
that the silent B-ESs are transcribed; however transcription is rapidly attenuated 
(Vanhamme et al. 2000). In addition, a recent study showed that a novel transcription 
regulator NLP (NucleoplasminLike-Protein) regulates the expression of silent ES. The 
depletion of NLP resulted in a 45-60 fold increase in the expression of the originally 
silent ES (Narayanan et al. 2011).  
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Telomere Position Effect (TPE) was proposed to play a critical role in the 
regulation of VSG (Dreesen et al. 2007), ever since the discovery that VSGs are 
exclusively expressed from sub-telomeric loci (De Lange and Borst 1982). Glover and 
Horn (2006) showed that an artificial seeding of telomeres affected the expression of Pol-
I reporter gene transcription in both life stages BF and PF.  However, not until recently it 
was shown that the depletion of the telomeric protein TbRAP1 caused the derepression of 
all silent B-ES linked genes (Yang et al. 2009). In addition, telomere length was shown to 
affect the rate of VSG switching, where cells with extremely short telomeres in 
telomerase null background had higher frequency of VSG switching as opposed to the 
cells that had longer telomeres (Hovel-Miner et al. 2012). These findings clearly support 
the hypothesis that telomeres influence the regulation of VSG.  
Homologous recombination is the major pathway for VSG switching (McCulloch 
and Barry 1999). In T. brucei, six TbRAD51 related proteins were identified (Proudfoot 
and McCulloch 2005) and among the six proteins, TbRAD51 and TbRAD51-3 deletion 
led to a decrease in VSG switching. In addition, a conserved key regulator of homologous 
recombination BRCA2, which binds to RAD51, was found in T. brucei. Deletion of 
TbBRCA2 led to decrease in the VSG switching frequency (Hartley and McCulloch 
2008). Deletion of TbTOPO3-! resulted in a significant increase in VSG switching 
frequency (Kim and Cross 2010). Finally, TbRMI-1, a homologue belonging to the RTR 
complex (REQ-helicase-toposisomerase III ! and RMI1/2), which suppresses 
inappropriate homologous recombination, resulted in a significant increase in VSG 
switching frequency (Kim and Cross 2011).  
Finally, DNA replication, one of the most critical processes for the survival of an 
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organism was carefully characterized lately by multiple groups and showed that the 
depletion of TbORC1 affected VSG silencing (Tiengwe et al. 2012a, Benmerzouga et al. 
2013). In the first study, Tiengwe et al. (2012) showed that the depletion of TbOrc1 
resulted in the derepression of metacyclic VSGs (mVSGs). Moreover, Benmerzouga et al. 
(2013) illustrated that depletion of TbORC1 affected VSG silencing in PF cells and BF 
cells as well as a significant increase in VSG switching frequency. Taken all of these 
studies together, it is evident that VSG regulation is a complex process involving multiple 
factors and multiple mechanisms. Therefore, it is possible that more factors will be 
identified in the near future. 
 
J-base Modification in T. brucei 
 
A novel modification found in kinetoplastids was first recognized by Bernards et 
al. (1984), where the digestion pattern of the two enzymes PstI and PvuII changed 
depending on whether the telomere was associated with an active or silent ES. PstI or 
PvuII were partially cleaved at a silent ES but fully digested at the same ES when it was 
active. However, this modification was completely absent in the procyclic form 
(Bernards et al. 1984). The first attempt to identify this putative nucleotide was done by 
Gommers-Ampt et al. (1991), where they found two unusual nucleotides pdJ and pdV. 
The pdV nucleotide was present in both life-stages but the pdJ nucleotide was exclusively 
expressed in BF cells and enriched at telomeric repeats. In addition, pdJ was found to be 
different than usual eukaryotic DNA modifications and exclusively expressed in 
kinetoplastids (Gommers-Ampt et al. 1993). The nucleotide pdJ, now known as base J 
(beta-D-glucosyl-hydroxymethyluracil), was physically shown to associate with silent but 
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not active VSG ESs by immunoprecipitating J (van Leeuwen et al. 1997). In addition, J 
was quite abundant at telomeres (van Leeuwen et al. 1998b), not found in insect stage 
form (van Leeuwen et al. 1998a) and targets not only telomeres but tandem repeats as 
well (van Leeuwen et al. 2000). J base is synthesized in two steps, first the thymidine is 
hydroxylated by two thymidine hydroxlyases JBP1 and JBP2 and then glycosylated by 
yet un-identified enzymes (Cliffe et al. 2009). Nevertheless, J is not a target for DNA 
glycosylases (Ulbert et al. 2004). Deletion of either JBP1 or JBP2 resulted in the decrease 
of the levels of J and J was completely abolished when both JBP1 and JBP2 were deleted 
(Cliffe et al. 2009). JBP1 and JBP2 null cells exhibited normal cell growth indicating that 
base J is not essential in T. brucei (Cliffe et al. 2009). Studies are on-going to deduce the 
functional relevance of base J in T. brucei. Moreover, base J showed functional relevance 
in other Kinetoplastida related organisms, Leishmania spp (van Luenen et al. 2012) and 
Trypanosoma cruzi (Ekanayake et al. 2011), where depletion of J resulted in increase of 
transcription of Pol-II transcribed genes. It remains to be determined whether presence of 
J in T. brucei is of any functional relevance (Borst and Sabatini 2008). 
  !
Telomeres and telomere complex 
 
Telomeres are nucleoprotein complexes located at ends of linear chromosomes!"Blackburn 1991). Telomere DNA usually consists of simple repetitive TG-rich 
sequences, and there is often a single-stranded 3’ G-rich overhang at the very end of the 
telomere (de Lange 2005). Telomeres are important for cellular homeostasis (Diotti and 
Loayza, 2011). Telomeres shorten with each round of cellular proliferation. This 
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phenomenon is known as cellular senescence (Blackburn 2001). Thus telomeres deduce 
the life span of a cell. The shelterin complex protects telomeres and mediates both 
telomere length and telomere protection (de Lange 2005). In humans, the telomere DNA 
is bound by two TTAGGG repeat binding factors: hTRF1 (Zhong et al. 1992,) and 
hTRF2 (Broccoli et al. 1997). These factors recruit the other telomeric factors, hRAP1, 
hTin2, hTPP1 and hPOT1 (de Lange 2005), which are all essential for cellular 
homeostasis (Diotti and Loayza 2011).  
In T. brucei, several essential telomeric proteins were identified (Li et al. 2005; 
Yang et al. 2009): TbTRF and TbRAP1 (Figure 1-3). TbTRF is the duplex telomere DNA 
binding factor. It plays an essential role in maintaining the telomere G-overhang structure 
(Li et al. 2005). TbRAP1 is the TRF-interacting factor and is essential for silencing ES-
linked VSG genes through a TPE-like mechanism (Yang et al. 2009). Additional factors 
are being characterized such as TbTIF ( TbTRF-interacting factor) and has been show to 
be important for VSG switching regulation (Jehi and Li, unpublished data). All T. brucei 
telomeric proteins are essential genes, making them an attractive therapeutic target 
against T. brucei (Li 2012). Nevertheless, the consequences of dysfunctional antigenic 
variation as a result of targeting these genes must be carefully characterized. T. brucei 
tightly regulates antigenic variation to prolong its survival in its mammalian host 
(Rudenko et al. 1998). It is possible that dysfunctional antigenic variation not only makes 
T. brucei vulnerable to complete elimination by host immune responses, but also, it 
makes it capable of escaping early immune detection (Dubois et al. 2005). Therefore, it is 
essential to dissect the consequences of deletion or depletion of essential genes to 
elucidate the most effective drug targets.   
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Figure 1-3: T. brucei’s telomere complex. TbTRF is the duplex telomere DNA binding 
factor (Li et al. 2005). TbRAP1 interacts with TbTRF and is essential for VSG silencing 
(Yang et al. 2009). TbTIF is also a TbTRF interacting factor and is important for VSG 
switching (Jehi and Li, unpublished data).  
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CHAPTER II 
MATERIALS AND METHODS 
Plasmids  
 For a full list of primer sequences refer to Appendix B. To generate psk-hygro-ko-
TbORC1, the 5`-UTR of TbORC1 was PCR amplified from T. brucei 927 genomic DNA 
using primers 1 and 2. The 3`-UTR of TbORC1 was PCR amplified using primers 3 and 
4. The UTR’s were digested and ligated into a pBlueScript vector. To generate pFLAG-
HA-HA (F2H)-ORC1, the TbORC1 N-terminal F2H-tagging construct, full-length 
TbORC1 (Tb11.02.5110) was PCR amplified using primers 5 and 6. The 5’ UTR region 
(~ 500 bp) was PCR amplified using primers 1 and 2. PCR products were inserted into 
pBlueScript to flank a cassette including the puromycin resistance gene (PURO), the 
alpha/beta tubulin intergenic sequence, and the F2H tag.  
 For yeast 2-hybrid analysis, the pACT2-TbORC1 construct was generated by 
amplifying TbORC1 using primers 5 and 7. The amplified TbORC1 was digested with 
BamHI and EcoRI.  Finally, the amplified TbORC1 ORF was inserted into the BamHI 
and EcoRI sites of pACT2. The pBTM116-TbORC1 construct was generated by 
amplifying TbORC1 using primers 8 and 9. The amplified TbORC1 was digested with 
EcoRI and BamHI. Finally, the amplified TbORC1 ORF was inserted into EcoRI and 
BamHI sites of pBTM116.  
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 To generate various TbTRF DNA binding mutant constructs, the N- terminus 
(NT) of TbTRF was amplified using primers 10 and 11. The C-terminus (CT) of TbTRF 
was amplified from TbTRF constructs harboring specific point mutations (made by Li, 
X) using primers 12 and 13. Two-step PCR was used to combine the two fragments. The 
first step used the overlapping fragments for extension at 53°C followed by a second step 
PCR that amplified TbTRF using primers 10 and 13. The TbTRF products harboring 
particular point mutations were ligated with a construct containing a Ty1 tag, BLE and 
PURO genes. 
 To target TbTRF DNA binding mutants in the HSTB261 reporter strain, TbTRF 
mutants were amplified using primers 10 and 13 and inserted into a Ty1 and BLE 
containing construct. For TbTRF MYB domain yeast-2-hybrid analysis, the full-length 
TbTRF harboring the following MYB domain mutations R348K, R298K, H346R and 
Q320S were fused to LexA binding domain and inserted into PstI and BamHI sites of 
pBTM116.  Full-length TbTRF was amplified from plasmids harboring individual point 
mutations using primers 14 and 16. The TbTRF MYB domain was amplified using 
primers 15 and 16.  
   To generate pFLAG-HA-HA (F2H)-TbTOR1, the TbTOR1 N-terminal F2H-
tagging construct, the NT of TbTOR1 was PCR amplified using primers 26 and 27. The 
5’ UTR region (~ 500 bp) was PCR amplified using primers 23 and 24. PCR products 
were inserted into similar construct described in generating the F2H-TbORC1 construct.  
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T. brucei strains 
Bloodstream antigenic type MITat 1.2 clone 221a T. brucei (VSG2-expressor) 
was used. Cells harboring the T7 polymerase and the tetracycline (Tet) repressor, single 
marker (SM, bloodstream) was used for conditional expression of the TbTRF double-
stranded RNA (dsRNA) or TbORC1 (dsRNA). All bloodstream (BF) cells were cultured 
in HMI-9 with appropriate drug selection. Lister 427 procyclic cells (PF) were used for 
procyclic form experiments. The 29-13 PF cells harboring T7 polymerase and the 
tetracycline (Tet) repressor were used for conditional expression of TbORC1 dsRNA.  
Cells carrying one endogenous allele of the N-terminus F2H tagged TbORC1 in 
BF form was generated by transfecting KpnI/SacII-digested pF2H-TbORC1. The C-
terminus of TbORC1 in PF cells was PTP tagged by transfecting SalI-digested pORC1-
PTP-NEO (Cells obtained from Concepción-Acevedo, J). 
TbORC1 RNAi cells were established by transfecting SacII-linearized 
pStLBFORC1 construct (obtained from Concepción-Acevedo, J) into SM cells. 
Transfections were performed using an AMAXA Nucleofactor (Lonza, Inc.) according to 
manufacture protocol.  
TbORC1 single knockout cells were generated by replacing the TbORC1 allele 
with a HYG gene using a targeting construct (See plasmids section). The TbORC1 
knockout targeting construct was linearized with XhoI and NotI, and transfected into 
TbORC1 RNAi cells. Correctly targeted clones were confirmed by Southern Blot 
analysis.  
For the TbTRF single knockout cells, TbTRF allele was replaced with a HYG 
gene by transfecting SM cells with a construct containing HYG gene (Li et al. 2005). The 
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construct was linearized with NotI and ApaI.  Upon Southern confirmation, cells were 
transfected with targeting constructs harboring the following point mutations in the MYB 
domain: R298K, Q320S, Q321S, H346R, R348K and R352K that were generated as 
described (See plasmid section). Constructs were linearized with SacII and targeted into 
the SM-TbTRF +/- strain. Surviving clones were selected and confirmed via Southern, 
Western and sequencing. Sequencing data were analyzed using SeqMan by aligning the 
wild-type TbTRF MYB domain with the sequenced results of the mutants. Only correctly 
incorporated point mutations in the MYB domain of TbTRF genomic DNA were used for 
further studies.  
Cells for the switching assays were established as described in (Kim and Cross 
2010) with minor modifications. First a single knockout of TbTRF was generated in 
HSTB261 strain. HSTB261 contains a blasticidin gene (BSD) at the active ES promoter 
and a puromycin gene (PURO) fused with Herpes simplex virus thymidine kinase 
(PURO-TK). Constructs were linearized with SacII and targeted into HSTB261-TbTRF 
+/- cells; surviving clones were selected and confirmed via Southern, Western followed 
by sequencing; only correctly incorporated point mutations in the MYB domain of 
TbTRF were used for the switching assays studies. At least two independent cell lines per 
mutant were characterized.  
The TbTRF-RNAi cells in HSTB261 strain were generated by targeting a NotI 
linearized PZJM!-TbTRF construct (Li et al. 2005). Surviving clones were screened for 
doxycycline sensitivity; only clones exhibiting strong depletion of TbTRF were used for 
VSG switching studies.  
 TbTEL2 RNAi cells in SM and in HSTB261 strain were generated by targeting a 
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NotI linearized PZJM!-TbTEL2 construct (made by Li, B). Clones were tested for 
doxycycline sensitivity; only clones exhibiting depletion of TbTEL2 were used for 
further studies. TbTEL2 RNAi was also introduced into a TbTEL2 +/- strain. One of the 
TbTEL2 alleles was replaced with a BSD gene. In addition, the other allele of TbTEL2 
was F2H-tagged using a F2H-targeting construct (made by Li, B). Finally, the F2H-
TbTOR1 cells were generated by targeting the NT tagging construct of TbTOR1 in the 
TbTEL2 -/RNAi cells.   
 
Generation of Anti-J-base serum 
Base J was conjugated to BSA or mKLH according to manufacture’s guidelines 
(Thermo Fisher Scientific). Briefly, the pH of EDC conjugation solution was adjusted to 
pH 6.0 with 0.1 M NaOH and 250 µl of 1 M imidazole. After adjusting the pH of the 
solution, J-base powder (obtained from Dr. Zhao) was mixed with EDC conjugation 
buffer. The mixture was incubated at 37 °C for 10 minutes. BSA and mKLH were 
prepared by adding 200 µl of ddH2O to each vial to make 10 mg/ml of BSA and 10 
mg/ml of mKLH. Dissolved J-base was added to the conjugating protein (BSA or 
mKLH) and rotated at room temperature (RT) for 2 hours. The conjugated hapten was 
purified by desalting. The concentration of J-base and conjugated-J-base was measured 
using Nanodrop (Thermo Scientific). For each individual conjugation, BSA or mKLH 
conjugated J-base was sent to ProSci for antibody generation. Bleeds were collected over 
8 weeks.  
For antibody (Ab) characterization, 1 µg of DNA from SM was blotted on to a N+ 
hybond membrane using a slot blot apparatus. The membrane was blocked for 1 hour in 
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PBST (10 mM Tris-HCl, pH 7.4 0.02% Tween-20) with 5% milk powder, washed 3 
times with PBST, and incubated with J serum diluted in PBST + 2% milk for 2 hours. 
The blot was washed 3 times with PBST, incubated with secondary Ab diluted in PBST + 
2% milk for 1 hour, washed 3 times with PBST and developed with ECL.  
 
Chromatin IP (ChIP)  
~1x108 cells were harvested and fixed with 1% formaldehyde for 20 minutes at 
room temperature. T. brucei BF cells were lysed and sonicated using a Bioruptor!300 
for 4 cycles with high output 30s on/off per cycle. Lysates were incubated using 
Dynabeads® with or without specific antibodies to immunoprecipitate protein-DNA 
complexes. For PF of T. brucei, cells were lysed and sonicated using a Bioruptor!300 
for 10 cycles with medium output 30s on/off per cycle. Lysate was subjected to 
immunoprecipitation using IgG Sepharose 6 Fast Flow. Prior to IP, beads were washed 
and equilibrated following manufacture’s protocol. Immunoprecipitated DNA was 
purified using the Qiaquick spin PCR purification Kit (Qiagen) and analyzed by Southern 
hybridization using a telomere specific probe: TTAGGG. As a control for pull-down 
specificity, blots were hybridized with 50 bp repeats probe.  
 
RNA Isolation and Reverse Transcription 
Total RNA was extracted from cells using RNAstat (TEL-TEST, Inc) and purified 
with Qiagen RNeasy kit and treated with DNase (Qiagen). Reverse transcription was 
carried out using M-MLV (Promega) according to the manufacturer’s protocol. 
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Quantitative RT-PCR 
Quantitative real-time RT-PCR was performed using BioRad iTaq SYBR Green 
Supermix with ROX according to the manufacturer’s protocol. The amount of DNA was 
quantified by DNA Engine Opticon 2 (BioRad). Only primers giving specific PCR 
products were used. The normalized fold change in mRNA level was calculated 
according to the formula in appendix A. The Sequence of RT-PCR primers used in these 
studies can be found in Table S1 in (Yang et al. 2009).  
 
Western Blot 
For details regarding each antibody, refer to appendix D. In TbORC1-RNAi cells, 
F2H-TbORC1 was detected using 12CA5, monoclonal antibodies against HA. In 
TbORC1-PTP-NEO cell line, TbORC1-PTP was detected using protein A antibody. 
Rabbit antibodies specifically against VSG2, VSG13 and VSG9 were used to detect 
expression of these VSGs. Expression of LexA Binding Domain- and Gal4 Activation 
Domain-fusion proteins were detected using monoclonal antibody against LexA and 
monoclonal antibody against GAL4.  
For Western analysis in TbTRF mutants, TbTRF was detected using a lab 
antibody against TbTRF: 1260 or 1261 (Li et al. 2005). For Ty1-TbTRF we used the 
commercially available BB2 antibody. As a loading control we used anti-beta tubulin 
TAT-1 (Yang et al. 2009). In TbTRF RNAi cells, TbTRF was detected using the same 
antibody 1260, and as a loading control we utilized EF-2 antibody or antibody against 
H3.  
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Pulse field Gel Electrophoresis and In-gel Hybridization  
 Undigested chromosome DNA was prepared in the form of plugs. Approximately, 
120 million cells were harvested and washed with 1xTDB (5 mM KCl, 80 mM NaCl, 1 
mM MgSO4, 20 mM Na2HPO4, 2 mM NaH2PO4, 20 mM glucose [pH 7.4]). Cells were 
re-suspended in L-buffer (0.01 M Tris-HCl pH 7.6, 0.02 M NaCl, 0.1 M EDTA pH 8.0) 
to a final concentration of 4 x 108 cells/ml. Cells were incubated at 42-50 °C for 10 
minutes. An equal amount of 50 °C low melting agarose was added to cells and ~ 1x107 
cells were loaded in the plug preparing chambers. The DNA plugs were allowed to 
solidify at RT for 10 minutes. The plugs were put in L-buffer with 1% N-L sarcosyl and 
Proteinase K (100 µg/ml) for 48 hours. After 48 hours, plugs were washed with L-buffer 
twice for 10 minutes each. The incubation step, as mentioned above, was done for 
another 48 hours. After 48 hours, the plugs were washed with L-buffer twice for 10 
minutes each at 50 °C and then, the plugs were allowed to cool to 4 °C prior to running.  
In order to run PFGE, 3 liters of 0.5 x TBE (40 mM Tris-Cl pH 8.3, 4 mM boric 
acid, 1 mM EDTA) were prepared. Out of the 3 liters of 0.5 x TBE, 200 mls were used to 
prepare 1.2% agarose gel. The plugs were loaded and PFGE conditions were set as 
follows: initial pulse for 1500s, ending pulse for 700s, voltage at 2.5 V/cm for 120 hours 
at 14°C. After 120 hours, the gel was stained for 1 hour in 0.5 x TBE containing 1 "g/ml 
EtBr and washed for 30 minutes with ddH2O prior to scanning. After scanning, the gel 
was dried overnight using a gel dryer with frequent changes of whatman paper in the first 
2 hours.  
For in-gel hybridization, the gel was pre-hybridized at 50 °C in Church Mix (0.5 
M NaPi pH 7.2, 4 mM EDTA pH 8.0, 7% SDS, 1% BSA) for at least 30 minutes. 
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Meanwhile, oligonucleotides were labeled with ATP (#-32 P) using T4 polynucleotide 
kinase. A TelC4 oligonucleotide was used to detect the G-strand and a TelG4 
oligonucleotide was used to detect the C-strand. The latter serves as a loading control. 
The gel was hybridized with the radioactive probes at 50 °C in 25 ml Church Mix 
overnight, washed in 4 x SCC at 55 °C three times, each for 30 minutes. The final wash 
was done once in 4 x SCC with 0.1% SDS at 55 °C for 30 minutes. The radioactive gel 
was wrapped and exposed for both TelC4 and TelG4 hybridization (refer to Appendix A 
for formula). 
 
VSG Switching Assays 
VSG switching phenotypes were determined by transiently knocking down 
TbTRF transcripts. HSTB261-TbTRF-RNAi cells were maintained in the presence of 
blasticidin and puromycin to homogenize the cell population (VSG2-expressors). Cells 
were then allowed to switch in the absence of drug selection for 24 hours, with or without 
induction (200 ng/ml doxycycline). Plating efficiency was assessed to determine cell 
viability after TbTRF knockdown and this was taken into account to calculate the VSG 
switching frequency. Doxycycline was washed off TbTRF RNAi induced cells after 24 
hours, and the cells were allowed to recover. When the cells reached the same population 
doubling as without induction, ~ 0.5 million cells were added to a medium containing 4 
µg/ml Ganciclovir (GCV) and distributed into 3 x 96-well plates. Switchers were verified 
using a dot blot for VSG2 prior to deducing the switching frequency. In addition, 
switchers were verified for potential spontaneous mutations that result in false switchers 
by the analysis of puromycin sensitivity at 2 µg/ml. The switchers were collected and a 
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Raw Frequency (RF) was calculated, which is the number of switchers collected divided 
by the total number of cells plated. To determine cell growth, cells are plated in the 
absence of GCV and a plating efficiency (PE) was calculated, which is the number of 
wells exhibiting growth divided by the number of wells plated. Switching frequency was 
reported as the RF normalized with PE (Figure 2-1). 
 
Figure 2-1: The Switching Assay. Cells were maintained under the selection of 
blasticidin and puromycin until the initiation of the switching assay. To initiate the 
switching assay, selective drugs were removed and cells were allowed to switch. Cells 
were platted in the presence or absence of GCV (see text for details). The RF was 
determined from the cells platted with GCV. The PE was determined from the cells 
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platted in the absence of GCV. The RF was normalized with PE for the reported 
switching frequency.  
 
For TbTRF MYB domain mutants, single knockout and wild-type HSTB261 cells 
were maintained in the presence of blasticidin and puromycin to homogenize the cell 
population (VSG2-expressors). Cells were then allowed to switch in the absence of drug 
selection for 3 days. When cells reached comparable population doubling, the same 
switching assay as described above was carried out.  
Finally, for TbTEL2 switching assay, TbTEL2 transcripts were depleted for 72 
hours, when cells reached comparable population doublings as without induction the 
same switching assay as described above was carried out. 
 
Dot Blot 
Approximately 1-2 million cells were harvested at 2000 rpm at RT for 10 
minutes. Approximately 20 "l of medium was left behind. The pellet was re-suspended in 
the remaining medium. A Nitrocellulose membrane was pre-wet with ddH2O for 1 
minute and 1 x PBS for 5 minutes. Approximately 5 "l of cells were loaded as a dot on 
the membrane. The dots were allowed to dry for 5 minutes on the membrane before 
blocking. The membrane was blocked with 1 x PBST + 10% milk for 30 minutes. The 
hybridization was done with VSG2 antibody diluted in 1 x PBST + 5% milk for one hour. 
The membrane was washed 3 x with 1 x PBST, hybridized with secondary antibody 
ECL-IgG-anti-rabbit for one hour, and then washed 3 x with 1 x PBST.  
 
Immunofluorescence Analysis 
Immunofluorescence was carried out as described previously (Lowell and Cross 
! 32 
2004) with minor modifications. Briefly, induced (Day 0) and un-induced (Day 4) 
TbORC1 RNAi cells were harvested and fixed with 2% formaldehyde and permeabilized 
with 0.2% NP40 in PBS. After blocking with PBS/Gelatin, cells were incubated with 
Alexa-488 conjugated anti-VSG3 and Alexa-647 conjugated anti-VSG13. Cell images 
were captured using a DeltaVision image restoration microscope (Applied 
Precision/Olympus), deconvoluted by using measured point spread functions, and edited 
with Adobe Photoshop.  
 
Immunoprecipitation 
Approximately 1x108 cells harboring an endogenous TbORC1-PTP or WT427 (no 
tag control) were lysed by vortexing the lysate with acid washed glass beads for 40 
seconds ON/OFF intervals, repeated for 3 times. Protein extract was pre-cleared with pre-
washed protein G beads (Sigma). The pre-cleared lysate was immunoprecipitated using 
IgG Sepharose 6 Fast Flow (GE Healthcare). Prior to IP, IgG beads were washed, 
equilibrated following the manufacture protocol. The IP product was washed five times 
with TST buffer (50 mM Tris-buffer pH 7.6, 150 mM NaCl and 0.05 % Tween 20) and 
once with 5 mM NH4Ac (pH 5.0). The IP product was eluted with 2 M glycine pH 2.2. 
All buffers were supplemented with 1 mM PMSF, protease inhibitor cocktail for 
mammalian cells (Sigma), 4 "g/ml pepstatin A, and 0.5 mg/ml TLCK immediately before 
use. Samples were analyzed by Western blot.    
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Southern Blotting 
Genomic DNA was prepared using DNAzol. Briefly, 100 million cells were 
harvested, washed with 1 x TDB and re-suspended in 1 ml DNAzol. After 30 minutes, 
the samples were spun at full speed for 10 minutes, only the supernatant was transferred 
to a new tube and DNA was precipitated with 100% ethanol. The DNA was washed with 
70% ethanol and allowed to air-dry. The DNA pellet was re-suspended in 30 "l of TE 
buffer. DNA concentration was measured using NanoDrop 2000 (Thermo Scientific). 
Approximately 5 µg of digested DNA were loaded into a 0.7% agarose gel in 0.5 X TAE 
and ran at 100V until the orange dye reached the end of the gel. The gel was depurinated, 
denatured and then neutralized before blotting.  DNA was blotted on hybond Nylon 
membrane, cross-linked prior to hybridization, pre-hybridized with Church Mix and 
hybridized with the specific probe at 65 °C. The blot was washed three times in 15 
minute washing intervals with Church Wash at 65 °C, wrapped and exposed. 
 
Flow Cytometry 
For each analysis ~ 20 million cells were harvested by centrifugation at 1500 rpm 
for 10 minutes at 4 °C. Cells were washed twice with 1 x TDB + 2 mM EDTA solution 
then re-suspended in 200 µl of the same buffer. Cells were fixed by adding 2 ml of 70% 
ice-cold ethanol drop-wise while vortexing. Cells were stored at 4 °C for at least 12 
hours. Prior to FACS analysis, cells were harvested by spinning for 10 minutes at 1500 
rpm at 4 °C. Pelleted cells were re-suspended in 0.5 ml staining solution (1 x PBS + 2mM 
EDTA, 200 µg/ml RNAseA, 50 µg/ml Propidium Iodide). Cells were incubated at 37 °C 
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for 30 minutes in staining solution and then we proceeded with FACS (cell cycle 
analysis). Data was analyzed using FlowJo software. 
 
Yeast-two-hybrid Analysis 
 Proteins were fused to either a LexABD or a GAL4AD. Interaction was measured 
as an output of $-galactosidase activity, where transcription of $-galactosidase was a 
result of protein interaction. $-galactosidase cleaves $- O-nitro-phenyl-$-D-
galactopyranoside (ONPG), which serves as a readout for the assay. For each strain, at 
least three independent clones were tested in each assay. The average values and SD was 
calculated from the combined results.  
 
Isothermal Titration Calorimetry (ITC) 
 ITC was performed and analyzed by our collaborator (Li, X) using an iTC200 
microcalorimeter (MicroCal). To measure the TbTRF MYB-DNA interaction, the 
injection syringe was loaded with 40 "l of TbTRF MYB sample and the cell was loaded 
with 200 "l of telomere DNA in the form of oligonucleotides. As a control to TbTRF and 
telomere DNA interaction, the cell was loaded with 200 µl non-telomeric DNA (5’ GAA 
TCT GGT GAG AGC GAC CCC GAT GAC GG 3’). Typically titrations consisted of 20 
injections of 2 "l with the duration of each injection being 4 seconds. Between two 
injections, approximately 200 seconds were allowed to elapse so that samples reach 
equilibrium before re-injection. The data were analyzed using Origin 7.0 in order to 
determine the dissociation constant (Kd), as long as the heat curve could be fit to some 
mode. In the cases where there was no heat curve generated, Kd could not be determined. 
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CHAPTER III 
TRYPANOSOMA BRUCEI ORC1 IS ESENTIAL FOR CELL CYCLE 
PROGRESSION AND VSG SILENCING1  
Imaan Benmerzouga et al. 
ABSTRACT 
Binding of the Origin Recognition Complex (ORC) to replication origins is 
essential for initiation of DNA replication, but ORC has non-essential functions outside 
of DNA replication, including heterochromatic gene silencing and telomere maintenance. 
Trypanosoma brucei, a protozoan parasite that causes human African trypanosomiasis, 
uses antigenic variation as a major virulence mechanism to evade the host's immune 
attack by expressing its major surface antigen the Variant Surface Glycoprotein (VSG), 
in a monoallelic manner. An Orc1/Cdc6 homologue has been identified in T. brucei, but 
its potential involvement in VSG repression has not been thoroughly investigated. In this 
study, we show that TbORC1 is essential for cell cycle progression in mammalian-
infectious bloodstream form (BF). Depletion of TbORC1 resulted in derepression of 
telomere-linked silent VSGs in both BF and PF, cells. TbORC1 associates with telomere 
      
1 As it appears in the Journal of Molecular Microbiology, 87(1): 196-210 
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repeats but appears to do so independently of two known T. brucei telomere proteins, 
TbRAP1 and TbTRF. We conclude that TbORC1 has conserved functions in cell cycle 
progression and is also required to control telomere-linked VSG expression. This chapter 
presents the work done solely by the author. 
 
INTRODUCTION 
Faithful replication of DNA is critical for cell survival. DNA replication nucleates 
from sites known as replication origins (Gilbert 2001), where a pre-RC complex forms. 
The pre-RC complex is initiated by the binding of the ORC complex containing Orc1-
Orc6 to DNA (Nasheuer et al. 2002). The pre-RC complex recruits cdc6 (cell division 
cycle-6), which also binds the replicating DNA. Cdc6 recruits cdt1, which acts as an 
adaptor to recruit the MiniChromosome Maintenance (MCM) complex (MCM2 to 
MCM7) (Diffley et al. 1994; Speck et al., 2005; Chen et al. 2007). Successful assembly 
of the pre-RC complex allows licensing of replication origins and DNA replication can 
initiate. DNA replication is carefully coordinated with cell-cycle progression. In 
eukaryotes, this is achieved by the binding of the pre-RC complex to replication origins 
only in G1 phase so that entry to S-phase is regulated (Diffley 2004; Blow and Dutta 
2005).  
The pre-RC complex is assembled upon the exit of mitosis and through G1 phase. 
In budding yeast, ORC proteins associate with the chromatin throughout the cell cycle 
(Stillman 2005), CDC6 is phosphorylated by cyclin-dependent kinases (CDK) and 
degraded at the G1/S transition (Elsasser et al. 1999; Drury et al. 2000). However, in 
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mammalian cells, the ORC1 protein level is regulated during the cell cycle. In S phase, 
mammalian ORC1 is polyubiquitinated by the SCF complex, followed by degradation by 
the 26S proteasome (Mendez et al. 2002), but CDC6 associates with the chromatin 
throughout the cell cycle (Blow and Dutta 2005). 
ORC recognizes and binds to replication origins (Bell, 2002). ORC1 to ORC5 
have one or two winged helix (WH) motifs that are involved in DNA binding (Gajiwala 
and Burley 2000). They also have a central AAA+ ATPase domain, which is important 
for specific DNA sequence recognition (Bell 2002). ORC has roles outside of DNA 
replication, such as the heterochromatin formation in yeast (Foss et al. 1993; Micklem et 
al. 1993; Bell et al. 1993), heterochromatin formation in Drosophila (Pak et al. 1997), 
gene silencing in Plassmodium falciprium, the causative agent of malaria (Mancio-Silva 
et al. 2008), chromatin remodeling in mammalian cells (Prasanth et al. 2004; Prasanth et 
al. 2010), association with centrosomes and centromeres in mammals (Prasanth et al. 
2004;! Hemerly et al. 2009) and centromere identity in yeast (Koren et al. 2010). 
Interestingly, the DNA replication initiation function of ORC does not necessary overlap 
with its other functions (Chakraborty et al. 2011).  
In budding yeast, a mutation in ORC2 disrupted silencing at HMR and caused a 
cell-cycle arrest, in correlation with impaired DNA replication (Foss et al. 1993; Micklem 
et al. 1993). In Drosophila, ORC2 interacts with heterochromatin protein 1 (HP1) and 
mutant ORC2 caused a defect in HP1 localization (Pak et al. 1997). In P. falciprium, 
ORC1 is required for the silencing of the var genes, which are located at subtelomeres.  
In mammalian cells, ORC2 is tightly bound to heterochromatin, HP1-alpha and 
HP1-beta and the depletion of ORC2 disrupted HP1 localization (Prasanth et al. 2004). In 
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addition, ORC1 and ORC3 tightly bind HP1-alpha and as ORC2, the depletion of ORC3 
disrupted the localization of HP1-alpha (Prasanth et al. 2010). Moreover, the depletion of 
HP1 resulted in the loss of ORC2 binding to heterochromatin (Prasanth et al. 2010). 
Taking these studies together, the ORC complex is important for heterochromatin 
organization in mammalian cells.  
Both ORC1 and ORC2 associate with centrosomes (Hemerly et al. 2009) but 
ORC2 mediates chromosome segregation and is important for centrosome copy number 
(Prasanth et al. 2004). ORC6 is important for cytokinesis and localizes to kinetochores 
(Prasanth et al. 2002). In pathogenic yeast C. albicans, centromere and neocentromere 
origins are associated with ORC and are the first to fire in early S-phase. The association 
of ORC to centromeres was disrupted when the levels of Histone 3 (H3) was altered at 
centromeres. This study illustrates that the identity of centromeres, at least in C. albicans, 
is depicted by its heterochromatin, allowing it to be the first to fire during replication 
(Koren et al. 2010). Mammalian ORC proteins interact with the telomere protein TRF2, 
and this interaction is important for assembly of the pre-RC at the telomere (Tatsumi et 
al. 2008; Deng et al., 2009). In addition, mammalian TRF2 interacts with ORC1 through 
its N-terminus (Atanasiu et al., 2006) and it is possible that this association is important 
for heterochromatin formation at telomeres (Deng et al. 2009). Taking all of these studies 
together, it is clear that ORC has functions outside of DNA replication.  
Trypanosoma brucei is a protozoan parasite that causes African sleeping sickness 
in humans. T. brucei escapes the host immune system by regulatory switching its surface 
molecule, Variant Surface Glycoprotein (VSG). VSG expression is tightly regulated and 
many factors were reported to be involved in this regulation (see chapter I).  
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An Orc1/cdc6 homologue, hereafter known as TbORC1, was identified in T. 
brucei (Godoy et al. 2009).  The primary sequence of TbORC1 contains a nuclear signal 
(NLS) in its N-terminal region. It also contains Walker A and B motifs (Godoy et al. 
2009). It also contains sensor I and sensor II regions (Godoy et al. 2009). These features 
are typical of members of the pre-replication machinery having the AAA+ ATPase fold 
(Calderano et al. 2011). For sequence alignment analysis, refer to (Godoy et al. 2009). In 
addition, genome wide ChIP identified binding sties for TbORC1 along all megabase 
chromosomes. From these binding sites, ~ 20% appeared to be replicated in early S phase 
and are considered to be DNA replication origins. There are ~ 100 predicted origins of 
replication in T. brucei (Tiengwe et al. 2012a).  
 Additional ORC subunits have been described since the identification of 
TbORC1 such as Orc1-like or Orc1b and Orc4 (Dang and Li 2011; Tiengwe et al. 
2012b). As expected, TbORC1 is required for nuclear DNA replication in both PF and 
BF cells. However, no functional studies have been done to study the function of 
TbORC1 in gene silencing in T. brucei.  
In this study, we report that TbORC1 is critical for normal cell cycle progression 
and VSG regulation. We also report that TbORC1 associates with telomeres independent 
of two known T. brucei telomere factors. Our results show that depletion of TbORC1 
impaired normal progression of the cell cycle, and it resulted in the derepression of ES-
linked VSGs in both life stages BF and PF. Finally, TbORC1 associates with telomeres, a 
possible mechanism whereby TbORC1 regulates VSG expression. The author generated 
the following presented data. 
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MATERIALS AND METHODS 
Plasmids and T. brucei strains generated and used for these studies are described 
in chapter II. Detailed procedures for flow cytometry, q-RT-PCR, immunofluorescence, 
chromatin IP, yeast-two-hybrid, Western analysis and IP can be found in chapter II. 
 
RESULTS 
TbORC1 is required for cell cycle progression 
Previous studies have demonstrated that TbORC1 is essential for cell growth 
(Goody et al. 2009). In addition, a direct role of TbORC1 in DNA replication was 
demonstrated (Benmerzouga et al. 2013). Nevertheless, careful characterization of the 
functions of TbORC1 in antigenic variation was not performed. We established inducible 
TbORC1 RNAi in BF cells that produce a stem-loop dsRNA. We targeted a FLAG-HA-
HA (F2H) tag to the N-terminus of one endogenous TbORC1 allele to monitor the 
expression level of the F2H-TbORC1 protein after induction of RNAi. 
The induction of TbORC1 RNAi led to depletion of the F2H-TbORC1 protein in 
two independent clones and caused a growth defect (Figure: 3-1a). Particularly, when the 
same TbORC1 RNAi construct was introduced into TbORC1 single-allele knockout 
(SKO) cells, RNAi induction caused a more severe growth defect, arresting cell growth 
after only one day (Figure: 3-1a). The protein levels for TbORC1 were monitored using 
an antibody against F2H. Without any depletion, F2H-TbORC1 is detected (Day 0) and 
upon induction, F2H-TbORC1 is no longer detected using Western Blot analysis (Day 1 
and Day 2; Figure: 3-1b). 
In order to investigate the function of TbORC1 in cell cycle progression, we 
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looked at the cell cycle profiles upon the depletion of TbORC1 in BF cells by FACS 
analysis of Propidium Iodine stained cells. Looking at a normal cell cycle profile for BF 
cells, the first peak represents cells with 2C DNA content, where the second peak 
represents cells with 4C DNA content and the gate in-between 2C and 4C is the S-phase 
(Figure: 3-2a).  
 
 
Figure 3-1: Growth analysis for TbORC1 depleted cells. (A) Depletion of TbORC1 in 
BF cells resulted in a growth defect. A more severe growth defect or an arrest was 
observed when dsRNA of TbORC1 was expressed in a background of a single allele of 
TbORC1. The arrest occurred within 24 hours. (B) Confirmation of the depletion of 
TbORC1 in two independent clones upon the induction of TbORC1 stem loop dsRNA; 
clones B4 and B5. 
 
Analysis of the gating profiles generated from un-induced cells showed a normal 
distribution of cells with 2C (G1, ~ 56%), S (~ 8%) and 4C (G2/M, ~ 30%) DNA 
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contents. However, in TbORC1-depleted cells (at day 3), we observed a significant 
decrease in the number of 2C cells (~ 34%) and a significant increase in the number of 
4C (~ 48%) and S cells (~ 12%) (Figure: 3-2 a, b). Our data suggests that TbORC1 is 
essential for cell growth in the BF stage and is absolutely required for normal cell-cycle 
progression.  
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Figure 3-2: Cell cycle analysis of BF cells upon the depletion of TbORC1. (Top) Flow 
cytometry of BF TbORC1 RNAi cells. Three independent samples were analyzed and 
labeled as samples 1-3. (Bottom) Quantification of populations of cells at different cell 
cycle stages before (day 0) and after (days 1, 2 and 3) depletion of TbORC1. Unpaired t-
tests were performed to compare day 1, 2 and 3 values with the day 0 value. One asterisk, 
0.009 < P % 0.05; two asterisks, 0.0001 < P ! 0.009; three asterisks, P % 0.0001. 
 
 
TbORC1 is required for complete silencing of ES-linked subtelomeric VSGs 
The ORC1 subunit has been documented to play pivotal roles in transcriptional 
silencing in yeast (Foss et al. 1993; Micklem et al. 1993; Bell et al. 1993), 
heterochromatin organization in mammals (Chakraborty et al. 2011), and the metacyclic 
form of T. brucei (Tiengwe et al. 2012a). We investigated whether the depletion of 
TbORC1 would affect sub-telomeric silent VSGs. To do so, we looked at the steady state 
mRNA levels of various ES linked VSGs upon the depletion of TbORC1 in both PF and 
BF cells. In both cases, depletion of TbORC1 was confirmed.  
Quantitative real-time PCR (q-RT-PCR) measured the mRNA levels of several 
ES-linked silent VSGs before and after the TbORC1 RNAi induction. PF cells repress all 
VSGs and express procyclin as a surface molecule. We examined whether any 
derepression is taking place in PF TbORC1 depleted cells. TbORC1 depletion in PF 
caused a mild derepression of ES-linked VSGs (Figure: 3-3a), when compared with the 
derepression levels in BF cells. In BF cells, we observed a moderate derepression of the 
ES-linked subtelomeric VSGs (Figure: 3-3b).  
The de-repression levels for different VSGs in BF cells were various, ranging 
from 3-fold (VSG9) to as high as 6-fold (VSG11) on day 2 and from 4-fold (VSG16) to 
12-fold (VSG6) on day 4 of TbORC1 RNAi induction, respectively. As a control, several 
control genes located in the chromosome-internal loci, including rRNA, TbTERT 
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(telomerase protein component gene), TbPGI (Tb927.1.3830, which encodes glycosomal 
glucose-6-phosphate isomerase), TbRPS15 (Tb927.7.2370, a putative ribosomal protein 
gene), and the originally active VSG2 were analyzed for a potential global derepression 
phenomenon, however, we did not observe any significant changes in the mRNA levels 
of the control genes, further solidifying the conclusion that the depletion of TbORC1 
resulted in an increase in ES linked sub-telomeric VSG expression.  
 
Figure 3-3: qRT PCR analysis of various ES-linked subtelomeric VSGs in both PF 
and BF cells upon the depletion of TbORC1. Steady-state mRNA levels of several 
silent VSGs, the active VSG2, and control genes were analyzed by qRT-PCR, using 
tubulin gene as an internal loading control. The fold changes in mRNA level after RNAi 
induction are plotted. Day 0 values were set to 1. rDNA, TbTERT, TbPGI and TbRPS15 
!"
#"
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genes were analyzed as controls. Fold changes were averaged from at least three 
independent experiments. Standard deviations are shown as error bars. (A) PF cells (B) 
BF cells. 
 
In an attempt to confirm our data with protein expression of ES-linked VSGs, we 
tested the expression of VSG9 and VSG2 after depleting TbORC1. In agreement with the 
our qRT-PCR results, upon the depletion of TbORC1, originally silent VSG13 and VSG9 
protein levels were expressed by day 4. (Figure: 3-4). These data suggest that TbORC1 
plays a critical role in silencing ES-linked VSGs.  
 
Figure 3-4: Depletion of TbORC1 resulted in derepression of ES-linked VSG 
expression. Western analysis of the following VSGs: VSG2, VSG13 and VSG9. The 
VSG2 is the original active VSG in these cells. The expression of any other VSG 
(VSG13 and VSG9) indicates a derepression phenotype. Upon the depletion of TbORC1, 
both VSG13 and VSG9 were expressed by day 4 of TbORC1 depletion, in addition to 
VSG2. Tubulin was used as a loading control. 
 
To test whether the derepressed VSGs are expressed simultaneously within the 
same cells, we carried out IF analysis using antibodies specific to two silent VSGs, VSG3 
and VSG13. As shown in Figure 3-5, no VSG3 or VSG13 expression was detectable 
before the induction of TbORC1 dsRNA. In contrast, by day 4, we can see a clear 
expression of both VSGs in the same cells, indicating that different silent ES-linked 
VSGs can be derepressed simultaneously in TbORC1 depleted cells.  
In addition, we stained the cells with both anti-VSG2 antibody and another 
antibody specific to the silent VSG3 or VSG13. After TbORC1 RNAi induction, we 
observed that both VSG13 and VSG3 are derepressed while VSG2 remained active 
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(Figure: 3-6), which is consistent with our qRT-PCR data (Figure: 3-3).  
 
 
 
Figure 3-5: Silent VSG derepression in TbORC1 depleted cells. Two silent VSG 
proteins can be expressed simultaneously on the surface of a single TbORC1-depleted BF 
cell. VSG2-expressing BF cells were examined by immunofluorescence at indicated time 
points after TbORC1 RNAi induction. Cells co-expressing the silent VSG3 and VSG13 
were visible 4 days post TbORC1 RNAi induction. A single layer of the z-stack images 
was shown for each time point to better illustrate the expression of derepressed VSGs and 
! 47 
their localization. 
 
 
 
 
Figure 3-6: Silent VSGs are expressed in TbORC1 depleted cells. (A) The originally 
active VSG2 is co-expressed with VSG13 upon the depletion of TbORC1. (B) Similarly, 
the originally active VSG2 is co-expressed with VSG3 upon the depletion of TbORC1 
(Note: The original population expresses VSG2 prior to the depletion of TbORC1).  
 
Finally, VSG2 antibody (the active VSG) was so diluted that VSG2 appeared as a 
punctate stain on the surface of the cells (Figure: 3-6). To rule out the possibility that the 
starting populations were not VSG2 expressers, the same populations were stained with a 
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higher concentration of VSG2 antibody and indeed, the starting population were VSG2 
expressers (Figure: 3-7). 
 
 
Figure 3-7: TbORC1 cells originally express VSG2. Cells were examined using rabbit 
antibody against VSG2. DAP1 was used to stain DNA (nucleus and kinetoplast). A stack 
of images was taken for each cell, but only one image is shown.  
 
TbORC1 associates with telomeres 
In mammals, Orc1 interacts with the telomeric protein TRF2 and TERRA, the RNA 
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transcripts of telomeres (Atanasiu et al. 2006 Tatsumi et al. 2008; Deng et al. 2009). 
TbORC1 is enriched at subtelomeric loci (Tiengwe et al. 2012a), hinting to the possible 
involvement of TbORC1 with telomeres; hence we asked whether TbORC1’s effect on 
antigenic variation is due to its association with telomeres. To test this possibility, we 
performed chromatin IP (ChIP) in both BF cells expressing F2H-TbORC1 (Fig. 3-8, a & 
b) and in PF cells expressing TbORC1-PTP (Fig. 3-8, c & d). The PTP tag contains two 
protein A and one protein C peptide separated by a TEV cleavage site (Schimanski et al. 
2005). TbORC1 proteins were immunoprecipitated using anti-HA antibodies (F2H-
TbORC1) or IgG coupled sepharose beads (TbORC1-PTP). Precipitated DNA was 
analyzed by slot blot followed by hybridization with a telomeric probe and quantified as a 
percent of the input. 
  We found that telomere DNA was significantly enriched in precipitated fractions 
in both BF (Figure: 3-8 a, b) and PF cells (Figure: 3-8 c, d). As a negative control, wild-
type cells without HA or PTP tag were precipitated with the respective antibodies (HA 
antibody in BF cells and IgG in PF cells). Negative controls did not precipitate down the 
telomere DNA, illustrating the specificity of the outcome of our ChIP. Therefore, 
TbORC1 appears to associate with the telomere DNA. However, TbORC1 association is 
not as much as TbTRF, when used as a positive control in ChIP. TbTRF appears to bind 
telomere DNA in a much higher amount (Figure: 3-8 a). 
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Figure 3-8: TbORC1 associates with telomeres in BF and PF cells. (A) ChIP of 
TbORC1 in BF cells, TbORC1 was F2H tagged and precipitated with an HA antibody to 
determine the specificity of the signal, a pull down with the HA antibody in an un-tagged 
cell line was performed. ChIP of TbTRF was carried as a positive control to telomere 
binding. Average enrichments were calculated from 15 independent experiments, and 
standard variations are shown as error bars. P values of unpaired t-tests are shown for 
indicated pairs of data. (B) Slot blot representation of TbORC1 binding to telomeres in 
BF cells. (C) ChIP of TbORC1 in PF cells, TbORC1 was PTP tagged and precipitated 
with IgG beads. To determine the specificity of the signal, a pull down with the IgG 
coupled beads was done in an un-tagged cell line. Average enrichments were calculated 
for 4 independent experiments, and standard variations are shown as error bars. (D) Slot 
blot representation of TbORC1 binding to telomeres in PF cells. Probes used are 
indicated on top.  
 
TbORC1 associates with telomeres independent of known telomere factors TbTRF and 
TbRAP1 
To study how TbORC1 is recruited to telomeres we investigated whether the 
association of TbORC1 to telomeres is a result of interaction with TbTRF or TbRAP1. 
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Yeast-two-hybrid analysis indicated that there was no interaction of TbTRF or TbRAP1 
with TbORC1 in vitro (Figure: 3-9). In addition, we tested the interaction of TbORC1 
with TbRAP1 and TbTRF in TbORC1-PTP tagged cell line, where immunoprecipitation 
was performed using IgG sepharsoe beads and any immunoprecipitated proteins were 
eluted after stripping. As indicated in figure: 3-10, when TbORC1 was pulled down, 
TbRAP1 or TbTRF was not present. However, they were present in the supernatant 
fraction, the fraction prior to immunoprecipitation, further confirming the lack of 
interaction in vivo between TbORC1 and TbTRF or TbORC1 and TbRAP1. These data 
are in agreement with our in vitro data.  
 
 
 
Figure 3-9: Yeast-two-hybrid analysis of the interaction of TbORC1 with TbTRF or 
TbRAP1. (A) $-galactosidase activity measurement of the in vitro interaction between 
TbORC1 and TbTRF or TbORC1 and TbRAP1. (B) Western analysis to confirm the 
expression of GAD-TbTRF, LexA-TbRAP1, GAD-TbORC1 and LexA-TbORC1. 
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Figure 3-10: TbORC1 does not interact with TbTRF or TbRAP1 in vivo. Immuno-
precipitation of TbORC1 in TbORC1-PTP expressing PF cells using IgG coupled beads 
or no antibody (No AB = non-coupled protein G beads). Cell lysate and precipitation 
products were analyzed by Western using antibodies against protein A, TbTRF or 
TbRAP1 as marked. 
 
Since the interaction between known telomeric proteins and TbORC1 was 
negative, we expected that the protein levels of TbTRF or TbRAP1 would not 
significantly change upon the depletion of TbORC1. In addition, the association of 
TbTRF and TbRAP1 to telomeres will not be significantly affected upon the depletion of 
TbORC1. To test the latter, we performed ChIP of TbTRF or TbRAP1 in the presence or 
absence of TbORC1 and report no significant changes in the association of TbTRF or 
TbRAP1 to telomeres upon the depletion of TbORC1 (Figure: 3-11). As for the protein 
levels of TbTRF and TbRAP1, we do not report any significant changes in their protein 
levels upon depletion of TbORC1 (Figure 3-12).  
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Figure 3-11: Association of TbTRF or TbRAP1 with telomeres in the presence or 
absence of TbORC1. (A) ChIP of TbTRF in presence or absence of TbORC1, no 
significant changes in the association of TbTRF with telomeres in the presence or 
absence of TbORC1. 50 bp repeats was used as binding specificity control, in that TbTRF 
specifically binds TTAGGG repeats. (B) ChIP of TbRAP1 in presence or absence of 
TbORC1; there were no significant changes in the association of TbTRF with telomeres 
in the presence or absence of TbORC1. Tubulin was used as binding specificity control 
for TbRAP1. In both ChIPs, wild-type cells were tested for the association of TbTRF and 
TbRAP1 with telomeres and no significant changes were observed with or without dox, 
validating our observations, that they are TbORC1 specific.  
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Figure 3-12: Depletion of TbORC1 did not affect TbTRF or TbRAP1 protein levels. 
Western analysis of TbTRF and TbRAP1 protein levels in the presence of TbORC1 (Day 
0) and in the absence of TbORC1 (Days 2, 4). No significant changes in the protein levels 
were observed.  
 
DISSCUSSION 
TbORC1 and cell cycle progression 
  Our data collectively demonstrated that TbORC1 is critical for normal cell cycle 
progression. Upon the depletion of TbORC1, we observed a significant decrease in 
population in G1 phase, significant increase in the population in S phase and G2/M 
phase. To further understand these observations, we labeled bulk DNA in BF cells with 
BrdU for the last 24 h of total TbORC1 RNAi induction time. During this labeling 
period, we expected that replicating cells were BrdU-positive while cells that had arrested 
before the labeling period would remain BrdU-negative. Without TbORC1 depletion, 
90% of cells incorporated BrdU. Upon TbORC1 depletion for 3 days, 73% of cells did 
not incorporate BrdU, indicating impaired DNA replication. In addition, there was an 
increase in cells with aberrant DNA content, such as cells with multiple nuclei (BrdU 
experiments were performed and analyzed by Concepción-Acevedo, J). Collectively, this 
indicates that TbORC1 plays an important role in DNA replication.  
Prior to our cell-cycle studies, we expected that the depletion of TbORC1 would 
arrest cells in S-phase, and hence we would observe a dramatic increase of cells in the S-
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phase. However, this was not the case in our cell cycle analysis. There are two possible 
explanations for these observations. First, although TbORC1 was the first DNA 
replication homolog identified in T. brucei, there are additional factors that have been 
identified, Orc1-like Orc4, and Orc1b (Dang and Li 2011; Tiengwe et al. 2012b), and 
these factors can proceed with DNA replication in the absence of TbORC1 –although not 
efficiently. The second explanation, which is more likely, is that TbORC1 depletion is 
not equivalent in all the cells in an unsynchronized population, where cells with greater 
depletion of TbORC1 arrested at S-phase and the cells with moderate depletion of 
TbORC1 was able to escape an S-phase arrest.  
Replication is regulated in budding yeast by the regulation of CDC6, where the 
CDC6 is phosphorylated and targeted for degradation preventing re-replication (Elsasser 
et al. 1999; Drury et al. 2000). Also, replication is regulated in mammals as described 
earlier (Mendez et al. 2002). However, little is known about the regulation of replication 
in T. brucei. TbORC1 was able to complement the temperature sensitive phenotype of a 
budding yeast cdc6 mutant (Goody et al. 2009) and therefore may function as a CDC6 as 
well. This could explain why cells with aberrant DNA content arise upon the depletion of 
TbORC1 in BF cells. It is possible that TbORC1 is not only required for replication, but 
also to regulate replication, and although other DNA replication factors are present (Orc4 
and Orc1b), the absence of regulating the entry to S-phase creates cells with aberrant 
DNA content. Cells with aberrant DNA content cannot divide and hence a dramatic 
G2/M arrest was observed. We observed cells with multiple nuclei in BF cells upon the 
depletion of TbORC1, consistent with the lack of the regulation of DNA replication. 
Studies have just begun to understand nuclear DNA replication in T. brucei and further 
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studies are required to address the possibilities presented. For instance, is the function of 
TbORC1 in nuclear DNA replication affected if Orc4 and Orc1b genes were deleted? 
What happens to replication if Orc4 was depleted or Orc1b? Is this phenotype stronger 
upon the depletion of TbORC1? These studies are necessary to explain the phenotypes 
observed in this study. Future experiments should address these questions. 
 
TbORC1 and antigenic variation 
The ORC complex is known to play important roles not only in DNA replication 
but other cellular processes including heterochromatin organization, mitotic checkpoint 
assembly and cell-cycle progression (Sasaki and Gilbert 2007; Chakraborty et al. 2011). 
The association of ORC subunits with HP1 in Drosophila and Xenopus (Pak et al. 1997; 
Huang et al. 1998), recruitment of Sir1 in budding yeast to establish heterochromatin in 
mating type silencing (Triolo and Sternglanz 1996), the binding of Orc1 to HM silencer 
and the cooperation of Orc1 with Sir2 and Sir4 in Kluyvereromyces lactis for the 
formation of heterochromatin structure at telomeres (Hickman and Rusche 2010) 
illustrates the importance of the role of the ORC complex and subunits in 
heterochromatin organization. 
Trypanosoma brucei regulates VSG expression through mono-allelic expression 
of VSG. The regulation involves multiple pathways and multiple proteins, including 
heterochromatin organization (Hughes et al. 2007; Figueiredo and Cross 2010; Stanne 
and Rudenko 2010#!Wang et al. 2010; Denninger et al. 2010). In this study we show that 
depletion of TbORC1 resulted in a significant increase in silent B-ES linked VSGs in both 
insect stage form and bloodstream form stage. Nevertheless, how TbORC1 influences 
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VSG silencing is not known. It is possible that the role of ORC in heterochromatin 
organization is conserved from protozoans to mammals. We did test the possibility that 
the depletion of TbORC1 results in the opening of heterochromatin through FAIRE 
analysis (data not shown); however, our data did not illustrate such a phenotype. The 
FAIRE assay, however, is probably not sensitive enough to detect subtle changes in 
chromatin structure in TbORC1-defective cells.  
In addition, it is tempting to speculate that TbSir2rp1 may play a role in 
establishing the heterochromatin, once its recruitment is initiated via TbORC1 (such as 
the case in K. lactis), but two forces oppose this idea. First, the depletion of TbSir2rp1 in 
T. brucei did not result in an increase in B-ES linked VSG transcripts (Alsford et al. 
2007). Second, there is a lack of a necessary bromo-adjacent homology domain (BAH) in 
TbORC1 (Tiengwe et al. 2012b). This domain is necessary for binding to nucleosomes, 
such as the case in budding yeast (Triolo and Sternglanz 1996). It is also possible that 
TbORC1 interacts with a yet un-identified factor that harbors a heterochromatin 
remodeling activity such as methyltransferase, where the recruitment of TbORC1 to 
replication origins and its interaction with this unknown protein modifies the histones on 
chromatin for silencing as its been shown in yeast (Krogan et al. 2002). Many 
possibilities remain to be tested in order to unwind the molecular mechanism by which 
TbORC1 affects VSG silencing. We only showed that TbORC1 associates with telomeres 
and it remains possible that this recruitment is facilitated by a role of TbORC1 in 
heterochromatin organization at telomeres that is yet not studied. Nevertheless, 
TbORC1’s conserved function in DNA replication, its effect on VSG silencing, and its 
divergence from mammalian ORC1 (Godoy et al. 2009) makes the targeting of pre-
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replication machinery in trypanosomes a future therapeutic intervention (Calderano et al. 
2011).  
 
TbORC1 at telomeres 
ORC interacts with mammalian TRF2 (Atanasiu et al. 2006; Deng et al. 2009) 
and maintains heterochromatin structure at telomeres (Hickman and Rusche 2010). Since 
VSG genes are located at sub-telomeres (De Lange and Borst 1982), we postulated that 
TbORC1’s role in antigenic variation could be due to its association with telomeres. 
Indeed, we show that TbORC1 associates with telomeres in both life stages, but not as 
strongly as TbTRF, the telomere binding protein. Recently it was shown that TbORC1 
appears to associate with subtelomeric regions containing VSG expression sites at a 
subset of T. brucei megabase chromosomes (Tiengwe et al. 2012a). The association of 
TbORC1 with VSG expression sites and telomeres may be important for TbORC1’s 
function in T. brucei antigenic variation.  
We also investigated whether this recruitment is dependent on one of the only two 
known telomere factors in T. brucei TbRAP1 (Yang et al. 2009), or TbTRF (Li et al. 
2005) or both. Since the role of TbRAP1 in the regulation of antigenic variation is well 
documented (Yang et al. 2009), we hypothesized that TbORC1’s role in antigenic 
variation may be due to its direct interaction with TbRAP1, consequently, its deletion 
affected either the protein levels of TbRAP1 or TbRAP1’s recruitment to telomeres. 
However, we did not observe any significant changes in TbRAP1 protein levels or its 
recruitment to telomeres upon the depletion of TbORC1. This illustrates that the role of 
TbORC1 in antigenic variation is probably independent of TbRAP1 pathway. 
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Another telomere protein that may facilitate the recruitment of TbORC1 to 
telomeres is TbTRF. In addition, TbTRF is important for the regulation of VSG switching 
(chapter IV). Since hORC1 was shown to directly interact with hTRF2 but not hTRF1 or 
hRAP1 (Atanasiu et al. 2006), and TbTRF and hTRF2 have a similarity in function (Li et 
al. 2005), we hypothesized that TbORC1 is recruited to telomeres through the interaction 
with TbTRF. We tested the interaction between TbTRF and TbORC1 using in vivo and in 
vitro approaches, and we did not detect any interaction. We also tested the possibility that 
the depletion of TbORC1 may affect TbTRF association at telomeres or TbTRF’s protein 
levels, and since the protein interaction data provided no support for such a possibility, it 
was not surprising that we did not report any changes in TbTRF protein levels or 
recruitment to telomeres upon the depletion of TbORC1. This is also not surprising, since 
hORC1 interacts with the N-terminus of hTRF2 (Atanasiu et al. 2006; Deng et al. 2009), 
and TbTRF lacks this domain. How TbORC1 goes to the telomeres is a question for 
active investigation. Future experiments should provide answers to these questions. 
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CHAPTER IV 
CHARACTERIZE THE FUNCTIONS OF TTAGGG REPEAT BINDING FACTOR IN 
TRYPANOSOMA BRUCEI 
Imaan Benmerzouga et al. 
ABSTRACT 
Trypanosoma brucei is a protozoan parasite that causes sleeping sickness in 
humans and nagana in cattle. When inside the mammalian host, T. brucei cells stay in 
extracellular spaces and regularly switch their surface antigen, Variant Surface 
Glycoprotein (VSG), to escape the host’s immune responses. T. brucei expresses a single 
type of VSG at any time exclusively from one of nearly 20 identical VSG expression sites 
located next to the telomere. Monoallelic expression of VSG ensures that VSG switching 
is effective. We have recently found that RAP1, an intrinsic component of the T. brucei 
telomere complex, is essential for silencing subtelomeric VSG genes, indicating that the 
telomere structure is important for antigenic variation in T. brucei.  
Telomeres are nucleoprotein complexes located at the ends of linear 
chromosomes. Telomeres are essential for maintaining genomic integrity. We have 
identified T. brucei TRF as a duplex telomere DNA binding factor. However, its function 
in antigenic variation has not been elucidated. We successfully established T. brucei’s 
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strains with transient depletion of TbTRF. These cells will be used for further studies. 
Also, we solved the NMR structure of TbTRF DNA binding domain (MYB). We 
identified point mutations that weaken the DNA binding activity in vitro. These point 
mutations were successfully targeted in vivo in two independent T. brucei strains. Finally, 
we studied the DNA binding activity of TbTRF in the presence or absence of base J, the 
modified thymidine (beta-D-glucosyl-hydroxymethyluracil) found in Kinetoplastids, in 
vitro and we report no difference.  
 
INTRODUCTION 
Telomeres are specialized nucleoprotein complexes that protect the termini of 
chromosomes (Blackburn 1991). Mammalian telomeres are bound by TRF1 and TRF2 
(Zhong et al. 1992; Broccoli et al. 1997; Bilaud et al. 1997), both of which recognize the 
same sequence TAGGGTT (Court et al. 2005) and are essential for the integrity and 
function of telomeres (van Steensel and de Lange 1997; van Steensel et al. 1998; 
Karlseder et al. 1999; Smogorzewska et al. 2000; Sfeir et al. 2009). Trypanosoma brucei 
TRF binds telomeres and is important for end protection (Li et al. 2005).  
Both hTRF1 and hTRF2 were identified through the ability of each protein to 
bind telomere DNA through a distinct MYB DNA binding motif (Zhong et al. 1992; 
Broccoli et al. 1997; Bilaud et al. 1997). The hTRF1 binds telomere DNA through a 
single MYB domain composed of 62 amino acids at its C-terminus (Broccoli et al. 1997). 
The MYB domain in hTRF1 is homologous to the c-Myb DNA binding domain 
(Klempnauer and Sippel 1987). The c-Myb protein belongs to the family of myb protein, 
is constituted of 3 repeats R1-R3, where only R2 and R3 are required for DNA binding 
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(Bianchi et al. 1999). The c-Myb transcription factor is a sequence specific DNA binding 
protein that binds to TTACNG (Biedenkapp et al. 1988).  
The solution structure of hTRF2 and hTRF1 with telomere DNA showed similar 
results with a minor significant difference in that hTRF1 binds to telomere DNA more 
strongly than hTRF2 (Hanaoka et al. 2005). The hTRF1 and hTRF2 proteins have critical 
functions in telomere length regulation (Smogorzewska et al. 2000). In addition, 
mammalian TRF1 is important for telomere replication (Sfeir et al. 2009). In murine 
embryonic stem cells (mESs), TRF1 is critical for telomere integrity and chromosomal 
stability (Iwano et al. 2004). However, hTRF2 is most crucial for end-protection (van 
Steensel et al. 1998; Karlseder et al. 1999;), a role that has been well conserved even in 
ancient protozoa (Li et al. 2005). Particularly, both the dimerization domain and the hinge 
domain are critical for the role of hTRF2 in end-protection (Okamoto et al. 2013). In 
addition to end protection, hTRF2 promotes heterochromatin formation through TERRA 
and ORC recruitment at telomeres, particularly through its N-terminal domain where it is 
required for ORC1 interaction (Deng et al. 2009). The TRF2 homodimerization domain, 
in addition to the MYB domain, enhances strand invasion that may aid in T-loop 
formation (Amiard et al. 2007).  
Telomeres have long been proposed to regulate the expression of VSGs (Barry et 
al. 2003; Lira et al. 2007; Dreesen et al. 2007). Evidently, recent breakthrough findings 
showed an essential role for T. brucei telomeric protein RAP1 in silencing all silent ES-
linked VSGs (Yang et al. 2009). The structure of telomeres and the location of virulent 
genes adjacent to telomeres are means developed by parasites for survival (Li 2010).  
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Putative TTAGGG Repeat Binding Factor (TRF) was identified in T. brucei (Li et 
al 2005). TbTRF has significant sequence similarity to hTRF1 and hTRF2 at its C-
terminus, but low sequence similarity at its N-terminus (Li et al. 2005). In addition, 
TbTRF lacks the acidic or basic domain present in hTRF1 and hTRF2 respectively 
(Figure: 4-1).  
 
Figure 4-1: TbTRF domains. Schematic representation of the two domains in TbTRF: 
TRFH and MYB. TRFH domain is less conserved among other TRFs, but the MYB 
domain is quite conserved. For sequence identity similarity see (Li et al. 2005).  
 
Early characterization of TbTRF documented the significant role of TbTRF in 
telomere end protection, where depletion of TbTRF resulted in a dramatic loss of G-
overhang signal (Li et al. 2005). However, a role for TbTRF in antigenic variation was 
not reported.  
In this chapter, I present the successful transient depletion of TbTRF in four 
independent clones generated by the author, the TbTRF NMR structure generated by our 
collaborator, the identification of specific point mutations that affected the DNA binding 
activity of TbTRF in vitro generated by our collaborator, the targeting of these particular 
point mutations in the MYB domain of TbTRF in two different strains generated by the 
author, the role of TbTRF in VSG silencing generated by the author, the binding of 
TbTRF to base J in vitro generated by our collaborator and finally, the successful 
depletion of base J in vivo generated by the author.   
    
 
TRFH MYB 
1   13                    162        297          357  382 
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MATERIALS AND METHODS 
Plasmids generated for these studies and T. brucei strains generated for these 
studies can be found in the corresponding sections in chapter II. ITC analysis, ChIP 
analysis, Southern blot analysis, genomic DNA isolation and Western analysis detailed 
methods may be found in their corresponding sections in material and methods in chapter 
II. 
 
RESULTS 
The successful transient depletion of TbTRF in four independent clones in HSTB261 
strain 
TbTRF-RNAi cells were established in the HSTB261 reporter strain (refer to 
chapter II) by introducing an inducible RNAi expression vector PZJM$-TbTRF (Li et al. 
2005). HSTB261-TbTRF-RNAi clones were screened for doxycycline sensitivity at 200 
ng/ml. Clones that showed a reproducible arrest at 24 hours were further utilized and 
carefully monitored for growth by generating a growth curve (Figure 4-2).  
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Figure 4-2: Growth curve analysis for all TbTRF-RNAi clones. Four independent 
clones were established for TbTRF-RNAi studies: A7, A8, B1 and B2. For each clone, 
cells were induced with 200 ng/ml of doxycycline for 24 hours. Cells were then 
recovered by washing away doxycycline. As a control, wild-type cells were treated with 
doxycycline and washed following the same conditions as TbTRF-RNAi cells. Only cells 
with TbTRF-RNAi showed a growth arrest at 24 hours and not wild-type cells. 
  
 
TbTRF protein levels were examined upon the induction and recovery of TbTRF-
RNAi. As expected, TbTRF protein levels decrease at 24 hours, and upon the removal of 
doxycycline, cells recover and protein levels return to wild-type levels at 72 hours. 
Histone 3 (H3) or Elongation Factor-2 (EF-2) was used as a loading control (Figure: 4-3). 
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Figure 4-3: Western analysis for TbTRF in all TbTRF-RNAi clones to confirm the 
transient depletion of TbTRF. Cells were induced for 24 hours and doxycycline was 
washed away at 24 hours. Protein samples were collected for 24, 48 and 72 hours. TbTRF 
protein levels decrease at 24 hours and slowly increase to wild-type levels. At 72 hours, 
TbTRF protein levels return to wild-type levels (in agreement with the growth curve 
analysis).  
 
 
 
NMR structure of TbTRF MYB domain  
TbTRF has two domains that are essential for its DNA binding activity, the 
homodimerization domain TRFH and the MYB domain. In order for TRF to bind to 
DNA, two MYB domains must recognize the (TTAGGG)n sequence at telomeres in each 
strand of the DNA and homodimerization must occur between the two subunits that are 
already bound to DNA. As the MYB domain is the smaller domain (~ 100 bp), we 
utilized it and solved its NMR structure in collaboration with Dr. Zhao from Hong Kong 
Polytechnic University in China. The TbTRF MYB domain structure was compared with 
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its homologs (human and yeast species). The amino acid sequence of the TbTRF MYB 
domain is significantly different from that of other MYB domains. Nevertheless, the 
tertiary structure of the DNA binding domain of TbTRF consists of three helices. Helix 1 
is composed of 13 amino acid residues (S304-F316), helix 2 is composed of 9 amino acid 
residues (F323-R331) and helix 3 is composed of 11 residues (V339-G349) (Figure 4-4). 
 These helices are organized in the Helix-Turn-Helix (HTH) motif commonly seen 
in DNA-binding proteins (Figure 4-5a). To determine point mutations that would affect 
TbTRF’s DNA binding activity, the solved 3-D structure of the TbTRF MYB domain 
was compared with its homologs (human and yeast species) with respect to DNA 
interaction points. The following residues were found to be possibly critical for TbTRF’s 
DNA binding activity: R298, Q320, Q321, H346, R348 and R352 (Figure 4-4). The R298 
residue is critical for TbTRF’s DNA binding function because it implies the N-terminal 
loop of the HTH motif. The R348 residue specifically recognizes the G base in the major 
groove of DNA. Residues Q320, Q321 and R352 are critical for sugar-phosphate 
backbone recognition, while H346 forms salt bridges with the NT of TbTRF (Figure 4-
5b). 
! 68 
 
Figure 4-4:  TbTRF amino acid sequence. The three helices are indicated in brackets 
with helix 1 in red, helix 2 in purple and helix 3 in blue. The entire MYB domain is in 
green. The residues selected for mutational studies are indicated in red. Note that R298, 
Q320, Q321 and R352 are outside of any helix. Only H346 and R348 are located in helix 
3. The location of each residue with respect to TbTRF’s MYB domain HTH motif is 
indicated in figure (4-7b).  
 
 
Figure 4-5: NMR structure of TbTRF MYB domain. (Experiments and analysis were 
performed by Li, X). (A) TbTRF MYB domain NMR structure in orange; simulation of 
MYB domain (orange) binding to DNA (blue). (B) Identification of residues that may 
affect the DNA binding activity of TbTRF.  
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Based on the TbTRF MYB domain NMR structure, point mutations were 
generated with the goal of finding mutations that either weaken or abolish TbTRF’s DNA 
binding function in vitro.  The ultimate goal of these mutational studies was to 
successfully obtain viable T. brucei cells with these point mutations when they were 
targeted in vivo. The mutational studies had two directions: one was to change the 
original amino acid to an amino acid that had a side chain with an opposite charge, for 
instance, mutating arginine (R) to glutamic acid (E). The second direction of the 
mutational studies was to change the original amino acid to an amino acid that had a side 
chain with a similar charge, for instance: R to lysine (K). In the cases where changing the 
original amino acid to an amino acid holding an opposite charge, and the functional 
analysis did not exhibit dramatic changes in TbTRF’s DNA binding activity, no further 
mutations were carried out for that particular residue, for instance glutamine (Q) to serine 
(S) point mutation. In addition, if the in vitro expression of the MYB domain mutation 
was not successful (the protein was insoluble in E. coli), no further experiments could be 
carried out for that particular residue (ex. H346E). The following point mutations were 
generated and tested for the DNA binding activity in vitro R298E, R298K, Q320S, 
Q321S, H346R, R348E, R348K, R352E and finally R352K.  
 
DNA binding activity of TbTRF MYB domain mutants in vitro   
The following isothermal titration calorimetry (ITC) experiments and analysis 
were performed by Li, X. To analyze the DNA binding activity of the MYB domain 
mutations, ITC was used to measure the extent of binding by each presented mutation. 
Approximately 200 µM of protein (MYB wild-type or with a point mutation) was titrated 
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onto 10 µM of sequence of TTAGGG (double stranded DNA) or negative DNA (5’ GAA 
TCT GGT GAG AGC GAC CCC GAT GAC GG 3’). Binding was measured as the heat 
interaction generated from the titration of protein onto telomeric DNA. Both wild-type 
and negative controls were carried out prior to testing the point mutations (Figure 4-6). 
These experiments concluded that the conditions used were optimal to measure the 
interaction of MYB with telomere DNA. 
 
Figure 4-6:  In vitro DNA binding activity of TbTRF mutants using Isothermal 
Titration Calorimetry (ITC). (Experiments and analysis were performed by Li, X). (A) 
Interaction of wild-type MYB with telomeric DNA. The well- shaped curve indicates 
progressive heat transfer as shown in wild-type telomeric DNA. In addition the Kd was 
calculated from the heat curve using Origin 7.0. Tight interaction is translated by a low 
Kd value. (B) Lack of interaction of wild-type MYB with non-telomeric DNA (negative 
control). The Kd value could not be determined because there was no curve generated 
due to the lack of interaction.  
!"
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The dissociation constant (Kd) was extrapolated from the generated heat curves 
using the software origin 7.0, as long as the heat curve could fit to some mode. The 
dissociation constant indicated the extent of binding, where a stronger interaction had a 
lower Kd value (Kd = (A) (B)/ (AB), where AB is complex formation). Due to the lack of 
interaction in some of the TbTRF MYB domain mutants with telomeric DNA, the Kd 
could not be determined. These mutations were classified as point mutations that 
abolished the DNA binding activity in vitro. These point mutations were R298E, R298K, 
R348E and R348K (Figure: 4-7).  
 
Figure 4-7: TbTRF MYB domain mutants with abolished DNA binding activity in 
vitro. (Experiments and analysis were performed by Li, X). Measurement of the 
interaction between TbTRF MYB domain mutants and telomeric DNA. Due to the lack 
of interaction, no heat curve was generated and hence Kd could not be determined. R298 
and R348 residues are critical for telomere DNA interaction in vitro. 
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The Kd was calculated for the remaining point mutations, because there was some 
interaction and a heat curve was generated. These mutations were classified as point 
mutations that weaken the DNA binding activity of TbTRF in vitro. The point mutations 
were: Q320S, Q321S, H346R and R352K (Figure 4-8). 
 
   
Figure 4-8: TbTRF MYB domain mutants with weakened DNA binding activity in 
vitro. (Experiments and analysis were performed by Li, X). The progressive heat curve 
indicates interaction between TbTRF MYB domain mutants and telomeric DNA. The Kd 
was calculated from the heat curve using Origin 7.0. The Kd values were compared to the 
WT Kd value and these mutants were classified as mutations with weakened DNA 
binding activity in vitro. Note the high Kd value compared to WT. 
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Generation of TbTRF DNA binding mutants in vivo 
To generate TbTRF point mutations in vivo, we constructed targeting constructs 
that harbour the point mutations via two-step PCR as described in materials and methods 
(chapter II). The targeting constructs were introduced in a TbTRF -/+ strain, so that the 
only allele present for TbTRF would be the TbTRF allele harbouring the particular point 
mutation (Figure: 4-9).  
 
Figure 4-9: Generation of TbTRF MYB domain mutants in vivo. First a parental 
strain was generated where a single allele of TbTRF was replaced with the HYG gene. 
Amplification of the mutants is described in chapter II (material and methods; plasmids 
section). The constructs harbouring the specified point mutations were targeted into the 
parental cells (TbTRF -/+). Because the mutant allele was doubly marked with BLE and 
PUR, drug selection was utilized to obtain correctly incorporated mutants. Only cells that 
survived in a medium containing hygromycin, puromycin and phelomycin were 
collected. In addition, a quick PCR analysis was used to validate the incorporation of the 
point mutation prior to further validations. The following mutants were viable: R298K, 
Q320S, Q321S, H346R, R348K, R352K. However R298E, R348E and R352E cells were 
not viable, although we tried the targeting multiple times. TbTRF is an essential gene and 
we expected that cells would not be viable, if the point mutation was of great severity to 
TbTRF’s DNA binding activity in vivo.  
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All viable cells harboring specific point mutations were confirmed via Southern 
using the EcoRI enzyme for digestion and a 3’-UTR probe to differentiate between the 
WT allele and the mutant allele (Figure 4-9). Only two independent clones per mutation 
were sequenced. To sequence T. brucei’s clones, genomic DNA was isolated from each 
clone and the TbTRF MYB domain was amplified using primers 15 and 13 (Figure 4-10 
and appendix B). The samples were purified and sent to Genwiz for sequencing. The 
sequencing data were aligned with the wild-type MYB domain of TbTRF. Each mutation 
was incorporated at the expected position and no other mutations were present. Sample 
sequencing data is presented in (Figure 4-10).     
 
Figure 4-10: Representative sequencing data of TbTRF MYB domain mutations in 
T. brucei cells. Sequencing data of TbTRF MYB domain mutants were aligned with the 
wild-type MYB domain. Base pairs in red indicate the 3 or 2 or 1 base changes of the 
particular point mutation. Different amino acids are indicated in different colors.  
 
Finally, Western analysis was performed for one clone per mutation. Cells were 
tested for the presence of the mutant allele, which is Ty1-tagged, where the parental cells 
(TbTRF -/+) were not. Cells were tested for the presence of the tagged allele by 
hybridization with an antibody specific for Ty1. All mutants express Ty1-TbTRF 
(mutant) equally; wild-type Ty1-TbTRF was used as a positive control to compare the 
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expression and molecular weight of the mutants (Figure 4-11a). When an antibody 
against TbTRF was used, the Ty1-tagged mutants were detected by their change in 
molecular weight, where they were slightly larger in size (Ty1-TbTRF is ~50 Kda and 
wild-type TbTRF is ~ 45 Kda; Figure: 4-11b). 
 
 
 
Figure 4-11: Western confirmation of T. brucei cells harboring indicated point 
mutation in the MYB domain. Western blot analysis to examine the presence of 
functional TbTRF in TbTRF MYB domain mutants. Cells were detected for the presence 
of (A) Ty1-TbTRF or (B) TbTRF (see text for details). Overall, there were no significant 
changes in the expression levels of mutant TbTRF compared to wild-type. 
 
Upon the confirmation of each DNA binding point mutation, detailed growth 
analysis was performed for all the viable cells harboring particular point mutations in 
TbTRF’s MYB domain. We did not observe a significant overall change in the growth of 
these mutants (Figure 4-12).  
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Figure 4-12: Growth curve analysis of TbTRF MYB domain mutants. Growth 
progression of all mutants was carefully characterized over 7 days.  No overall significant 
changes were observed in the growth of TbTRF mutants. However, we did observe that 
the mutants that had weakened DNA binding activity compared to WT (R298K, H346R 
and R348K) had a slightly slower growth rate compared to the remaining mutants. 
However, the overall changes were not significant.  
 
 
Analysis of VSG silencing in TbTRF DNA binding mutants 
 
 In order to detect any possible role for TbTRF DNA binding mutants in VSG 
silencing, Western blot was carried out to look at the expression of a different ES-linked 
VSG other than the active VSG (VSG2). Only TbTRF-/R348K expressed VSG13 in 
addition to the originally active VSG2. This hinted to the possibility that perhaps this 
particular mutant is affecting VSG switching rather than silencing (Figure: 4-13a). In 
addition, VSG13 was detected in a Northern analysis for some sub-clones of TbTRF -
/R348K mutant (Figure 4-13b), further supporting our hypothesis that TbTRF DNA 
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binding mutants affect VSG switching and not VSG silencing. These data are in 
agreement with previous observations (Yang et al. 2009).  
 
  
Figure 4-13: Analysis of VSG silencing in TbTRF DNA binding mutants. (A) 
Western analysis of VSG2 and VSG13 expression in TbTRF mutants. Only TbTRF -
/R348K expressed VSG13 in addition to VSG2, further supporting our hypothesis that 
TbTRF may play a role in VSG switching and not VSG silencing. (B) Northern analysis 
of TbTRF -/R348K sub-clones. The TbTRF -/R348K mutant was sub-cloned and mRNA 
was isolated for several sub-clones. The expression of VSG13 was tested for several sub-
clones and VSG13 was detected only in TbTRF -/R348K sub-clone #20. TbTRF -/Q320S 
was used as a control (Western analysis did not detect any VSG13 expression in TbTRF -
/Q320S). 
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Targeting TbTRF MYB domain mutants into HSTB261 reporter strain  
TbTRF MYB domain mutants R298K, H346R, R348K and Q320S were 
introduced in HSTB261 starter strain with minor modifications (see material and methods 
section and figure: 4-14). Each mutant was confirmed with PCR, Western blot and 
sequencing. At least two different clones were generated per mutation. These clones will 
be used to perform future switching assays.  
 
 
 
Figure 4-14: Strategy to target TbTRF MYB domain mutants in the starter strain 
HSTB261. A single knockout allele of TbTRF was established as described in figure 4-
14. The point mutations were introduced into a construct that was marked with a BLE 
downstream of TbTRF ORF.  
 
 
J-modification in T. brucei does not affect TbTRF DNA binding activity in vitro and in 
vivo 
J base is a modification present at telomeres, where a thymidine residue is 
modified to J base. Since TbTRF is the only known direct telomere DNA binding factor, 
we sought to investigate TbTRF binding to J-modification at telomeres and whether or 
not TbTRF is indifferent to the presence of J modification at telomeres. Using ITC to 
measure the DNA binding activity of TbTRF in the presence or absence of J in vitro, we 
reported no difference (Figure: 4-15). TbTRF MYB domain was titrated onto a telomeric 
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sequence containing J (5`-GGTJAGGTTAGG-3`). The interaction was measured as 
described previously, where a well-shaped curve indicates interaction. In addition, a Kd 
value was determined from the heat curves. Whether TbTRF MYB was titrated onto a 
telomeric sequence containing J base or not containing J-base, the heat curves generated 
from the interaction did not differ significantly nor did the Kds. These curves were 
generated in collaboration with Dr. Zhao at Hong Kong Polytechnic University 
(Experiments were performed and analyzed by Li, X). 
 
 
Figure 4-15: J modification does not affect the telomere DNA binding activity of 
TbTRF in vitro. The TbTRF MYB domain interaction with telomere DNA was 
measured using ITC. TbTRF’s MYB domain was titrated onto a telomeric sequence 
containing J. The overall interaction did not differ significantly when compared to 
TbTRF’s MYB domain interaction with a telomeric sequence lacking J (Experiments and 
analysis were done by Li, X). 
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Successful depletion of J-base in vivo. 
To further investigate if this result was reproduced in vivo, first, successful 
depletion of J must be established. To deplete J, cells were treated with DMOG for 6 days 
at a 0.5 mM concentration. DMOG is a J synthesis inhibitor (Cliffe et al. 2012). As a 
control, cells were treated with DMSO in the same manner and for the same time length. 
As a control to either treatment, cells with no treatment were grown for the same time 
length. No growth defects were observed upon the addition of DMOG in two different 
strains SM and PVS-3-2-OD-1-1 (Figure 4-16), in agreement with previous observations 
(Cliffe et al. 2012). 
  
Figure 4-16: Growth curve analysis upon the addition of J-synthesis inhibitor 
(DMOG). No growth defects were observed when treating the cells with 0.5 mM of 
DMOG. Cells without treatment or DMSO treatment were carried out as controls. 
 
Finally, J-synthesis depletion was confirmed by looking at the VSG2 locus after 
PstI digestion in PVS-3-2-OD-1-1 strain, where VSG2 is silent. Recall that J is present in 
silent but not active ES. Therefore, we used this discrepancy to determine if our depletion 
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of J was successful. If J is present in the PstI digestion site, PstI enzyme cannot cleave 
that site and will cleave the following PstI site (as long as there is no J modification). If J 
is absent complete cleavage of PstI sites takes place. Because we used VSG2 NT as a 
probe, we were able to differentiate between partial and full cleavage of PstI sites.  In the 
absence of J, only one band is observed at 1.6kb due to complete cleavage. In the 
presence of J, some PstI sites are modified and therefore, partial cleavage is observed 
whenever there is J (see map for expected or possible sizes of partial cleavage, figure 4-
17a).  
Upon treatment with DMOG, the absence of J, we clearly observed the complete 
cleavage of PstI site at silent VSG2 locus. As a control, we ran PVS-3-2-OD-1-1 strain 
genomic DNA digested with PstI. Also we ran PVS-3-2-OD-1-1 strain genomic DNA 
treated with DMSO and digested with PstI. In both cases we observed partial cleavage of 
PstI site in VSG2 locus (9.6kb band) indicating the presence of J at one of the PstI sites 
present in the VSG2 locus. To validate the digestion pattern of the VSG2 locus SM strain, 
where VSG2 is active, genomic DNA was run as a positive control. The expected size of 
full cleavage, 1.6 kb, was observed. In addition, procyclic WT427 (cells that lack J-
modification) was carried out as a positive control. The expected size of full cleavage 
when PstI site is not modified was observed (Figure: 4-17b). 
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Figure 4-17: Confirmation of the depletion of J in vivo upon addition of the J-
synthesis inhibitor DMOG. (A) Map of VSG2 locus and expected bands upon PstI 
digestion. NT probe was used (pink line on map). If the PstI site is fully cleaved, only the 
1.6 kb band is observed. If J modification is present and depending on what PstI site is 
modified, various bands may be observed. See map. (B) Southern Blot analysis to 
confirm the loss of J-modification upon DMOG treatment. The expected 1.6 kb band 
when PstI sites were fully cleaved and when VSG2 NT was used as a probe was observed 
in the following sample: 1) cells lacking J (WT427), 2) in cells where VSG2 is active 
(SM), 3) Upon DMOG treatment in cells where VSG2 is silent (depletion of J). Partial 
cleavage is observed only in the PVS-3-2-OD-1-1 WT cells and cells treated with 
DMSO, indicating the presence of J in some of the population at a particular PstI site. 
(See text for more details). 
 
 
DISCUSSION: 
Trypanosoma brucei TTAGGG repeat binding factor 
Telomeres in T. brucei, like humans, consist of TTAGGG repeat tracts. However, 
only one telomere DNA binding protein was identified (Li et al. 2005). TbTRF was 
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specifically shown to bind to duplex TTAGGG DNA through EMSA experiments (Li et 
al. 2005). TbTRF was also shown to bind telomere DNA in vivo through ChIP analyses. 
Depletion of TbTRF led to dramatically reduced G-overhang signal characterized through 
in-gel hybridization studies. Therefore, TbTRF is a homologue of hTRF2 and, like 
hTRF2, is important for end protection (Li et al. 2005). TbTRF depleted cells acutely 
arrested at 24 hours, making the analysis of VSG silencing or VSG switching hard to 
perform. TbTRF like hTRF1 and hTRF2 contains a single MYB domain, a 
homodimerization domain, but lacks an N-terminal domain and has a less conserved 
hinge domain (Li et al. 2005). Despite the differences, hTRF1 was able to localize to the 
T. brucei telomere when expressed (Munoz-Jordan and Cross 2001). TbTRF is a 
homodimer, so in order for TbTRF to bind to telomeres, TbTRF needs both a MYB 
domain on each strand and the homodimerization activity of TbTRF. Therefore, we 
proposed that the disruption of TbTRF’s major function (DNA binding activity) through 
its MYB domain or homodimerization domain will provide us with a mechanistic 
understanding of the functions of TbTRF in VSG regulation. Being a small domain of 
only 60 amino acids (Li et al. 2005), we solved its NMR structure in collaboration with 
Dr. Zhao at Hong Kong Polytechnic University in China. The MYB domain of TbTRF 
forms a Helix-Turn-Helix (HTH) motif, a typical motif found in DNA binding proteins. 
Studies are on-going to solve the TbTRF homodimerization domain, which is ~ 150 
amino acids in length.  
Several point mutations were identified to weaken or abolish DNA binding 
activity in vitro. These point mutations were successfully targeted in vivo. Attempts to 
obtain the following TbTRF MYB domain mutants, R298E, R348E and R352E were not 
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successful. It is possible that the point mutation is deleterious and no viable cells could be 
obtained. However, further attempts to obtain these cells must be conducted prior to 
making this conclusion.  
We observed the expression of VSG13 in addition to VSG2 in TbTRF -/R348K. 
However, we did not observe this phenotype in other TbTRF MYB domain mutants. It is 
possible that the VSG expressed in the other mutants is not VSG13. To further examine 
this, a q-RT-PCR analysis for various ES-linked silent VSGs must be carried out and as 
an expectation, an expression of an additional VSG other than VSG13 should be 
observed. Another explanation could be the DNA binding activity of these mutants varies 
in vivo, where mutants with significantly less DNA binding activity affect VSG silencing. 
These studies will lead to an explanation to why only TbTRF -/R348K showed an 
increase in VSG13 mRNA levels and not any other mutant.  
 
TbTRF and antigenic variation 
VSG regulation is a crucial mechanism for T. brucei pathogenesis. There are two 
independent pathways for VSG regulation: VSG silencing and VSG switching. Many 
factors are involved in the regulation of VSG silencing including telomere proteins (Yang 
et al. 2009). In addition, VSG switching is regulated via telomere length (Hovel-Miner et 
al. 2012). Here we successfully established four independent clones where we can 
transiently deplete TbTRF in all four independent clones; these clones will be used to 
study the role of TbTRF in VSG switching. If TbTRF plays a role in VSG switching, then 
it is of great interest to study if any of the TbTRF DNA binding mutants affects VSG 
switching. To date, I successfully established some of TbTRF DNA binding mutants in 
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HSTB261 reporter strain. These point mutations weakened or abolished DNA binding 
activity of TbTRF in vitro. Point mutation in R348 and R298 to R348K and R298K, 
respectively, had abolished DNA binding activity in vitro. However, mutations in Q320 
and H346 to Q320S and H346R had weakened DNA binding activity in vitro, when 
compared to wild-type. All clones should be utilized to study antigenic variation 
controlled by TbTRF’s MYB domain. 
No VSG derepression was detected in TbTRF depleted cells (Yang et al. 2009). 
However, when the TbTRF DNA binding mutants were tested for a potential role in VSG 
silencing, only VSG13 expression was observed in TbTRF -/R348K mutant. We sub-
cloned the TbTRF -/R348K population, in order to understand the expression of VSG13 
in the TbTRF -/R348K population. Sub-cloning of TbTRF -/R348K resulted in one clone 
expressing VSG13 and the other clones did not. There are two possible explanations to 
these differences. The first explanation is that the mRNA of VSG13 in some sub-clones is 
not abundant and hence could not be detected with a Northern analysis. The second 
explanation is that the sub-clones that did not express VSG13 switched to a different 
VSG, other than VSG13. In order to determine what explanation is true, a q-RT-PCR 
analysis must be carried out for all TbTRF -/R348K sub-clones. If the first explanation 
were true, we would observe a significant fold change in the mRNA levels of VSG13 
among the sub-clones, when compared to the sub-clones where VSG13 was not detected. 
If the second explanation were true, the q-RT-PCR analysis would not detect any fold 
changes in VSG13 expression in the sub-clones where VSG13 was not detected and 
instead the expression of a different VSG is observed. Further experiments will provide 
an answer to our observations. 
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TbTRF and base J 
 Base J is quite abundant at telomeres (van Leeuwen et al. 1998b) and TbTRF is 
the only duplex TTAGGG binding factor known in T. brucei. However, for a long time it 
was not known whether the presence of this modification at telomeres affects the binding 
of TbTRF to telomeres. We analyzed the association of TbTRF with telomere DNA in 
the presence or absence of J both in vitro (experiments performed by Li, X). The titration 
of wild-type TbTRF onto telomeric sequence contacting J did not differ significantly 
from the titration of wild-type TbTRF onto telomeric sequence lacking J (data collected 
and analyzed by Li, X). We further will study this association in vivo using ChIP 
analysis. To do so, successful depletion of J must be established. We successfully 
depleted J using a J-synthesis inhibitor DMOG (Cliffe et al. 2012). DMOG was shown 
previously to deplete all J present in the genome (Cliffe et al. 2012). The absence of J did 
not affect cell viability (Cliffe et al. 2012).  
Since the absence of J did not affect cell viability, we expect that the binding of 
TbTRF to telomere DNA in vivo will not affected by the presence or absence of J. If 
TbTRF required the presence of J to bind to telomeres, it is expected that upon the 
depletion of J, cells are not viable, because TbTRF is essential (Li et al. 2005). 
Nevertheless, it was not the case previously (Cliffe et al. 2012) and it is not the case in 
our study, where the depletion of J did not affect cell growth. Taken these data together, 
it is evident that the presence of J in telomeric repeats in T. brucei does not affect 
TbTRF’s binding to telomeric DNA in vitro and the absence of J does not affect cell 
viability. Future studies will be needed to analyze the association of TbTRF to telomeres 
in the presence or absence of J in vivo. 
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CHAPTER V 
CHARACTERIZATION OF TRYPANOSOMA BRUCEI TEL2 
             Imaan Benmerzouga 
ABSTRACT 
 Trypanosoma brucei is a protozoan parasite that causes African trypanosomiasis. 
In their mammalian host, T. brucei cells regularly switch their surface antigen, Variant 
Surface Glycoprotein (VSG), to evade host immune attack. To maximize the efficiency 
of VSG switching, T. brucei expresses a single VSG exclusively from one of ~20 nearly 
identical VSG expression sites (ESs) located next to the telomere. Telomeres are 
specialized nucleoprotein complexes located at the ends of linear chromosomes. They are 
essential for chromosome stability and form a heterochromatic structure that can 
influence the transcription of genes located nearby. We have shown that one of the 
telomere-specific proteins (TbRAP1) is essential for VSG expression control, indicating 
that telomeres are important for virulence mechanisms in T. brucei. Tel2 was first 
identified in yeast and has been shown to be essential for telomere length maintenance. 
Subsequently, Tel2 homologues have been identified in different organisms including 
worm and human. However, different Tel2 homologues seem to have different functions, 
including circadian rhythm regulation, growth control, and telomere maintenance. Recent 
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studies showed that mammalian and yeast Tel2s regulate the protein stability of PI3-K 
related kinases (PIKK), which are key signal transducers in multiple signal transduction 
pathways involved in DNA damage repair/cell cycle checkpoint, degradation of mRNA, 
and gene expression control, explaining the versatility of Tel2 functions. 
An in silico approach was used to find putative TEL2 in T. brucei’s genome. 
Because telomeres are important for antigenic variation, we explored the potential role of 
putative TbTEL2 in telomere length maintenance, regulation of the protein stability of T. 
brucei’s PIKKs, which in turn, may be critical for telomere recombination, a major 
pathway for VSG switching. Inducible TbTEL2 RNAi cells have been established and 
only one T. brucei PIKK homologue was tagged with epitopes. The protein levels of 
TbTOR1 were examined after depletion of TbTEL2. Preliminary data suggest that 
putative TbTEL2 is indeed the TEL2 homolog in T. brucei.  
 
INTRODUCTION 
 In 1986, Lustig and Petes identified mutant strains that exhibited shorter 
telomeres. They named them tel1 and tel2.  Ten years later, the genes were cloned. In 
Saccharomyces cervisiae Tel2 mutants showed shortening in their telomeres (Lustig and 
Petes 1986; Runge and Zakian 1996). Tel2 caused the reversible repression of 
transcription genes located near telomeres, a phenomenon known as telomere position 
effect (Runge and Zakian, 1996). ScTel2 is important for cell viability. Cells lacking 
ScTel2 did not survive (Runge and Zakian 1996).  In addition, ScTel2 encodes a protein 
that binds telomeric DNA (Kota and Runge 1998). ScTel2p binds to single stranded 
telomeric DNA in vitro (Kota and Runge 1999). ScTel2 functions during DNA damage at 
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a specific step in the ATM/Tel1 pathway, it mediates the activation and localization of 
ATM/Tel1 to double strand break (Anderson et al. 2008). In Schizosaccharoyces pombe 
Tel2 physically interacts with all the phosphoinositide 3-kinase- related kinases (PIKKs) 
(Hayashi et al. 2007). In Caenorhabditis elegans, clk-2 encodes protein homologous to 
budding yeast Tel2p. It functions in telomere regulation, where clk-2 mutants have 
elongated telomeres and clk-2 over-expression leads to telomere shortening (Benard et al. 
2001). Clk-2 affects embryonic development and the temperature sensitive mutant leads 
to embryonic lethality at 25 ºC (Benard et al. 2001).  In mammalian cells Tel2 had no 
obvious telomere-related functions, however, it was essential for embryonic 
development, cell growth and the stability of ATM, mTOR and other PIKKs (Takai et al. 
2007). In addition, Tel2 can interact with each of the six mammalian PIKKs (Takai et al. 
2007).  
Telomeres are nucleoprotein complexes located at the ends of linear 
chromosomes and are essential for protection of chromosome ends. In addition, the 
telomeric heterochromatic structure affects transcription of genes located in subtelomric 
regions, phenomenon known as TPE. Several functions have been reported for Tel2 
homologs in different organisms, including telomere homeostasis. 
Putative TbTEL2 was identified by Dr. George Cross and in this chapter, the 
author shows preliminary data for the role of TbTEL2 in cell viability, telomere 
homeostasis, TbTOR1 stability and finally VSG regulation. My preliminary data suggest 
that like budding yeast Tel2, TbTEL2 is essential for cell growth and telomere 
hemostasis. Like mammalian TEL2, TbTEL2 affects the stability of TbTOR1 protein and 
finally, TbTEL2 affects VSG switching. 
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MATERIAL AND METHODS 
Plasmids and T. brucei strains generated for these studies can be found in chapter 
II. Western blot analysis, VSG switching and G-overhang analysis are described in 
materials and methods (Chapter II).  
 
RESULTS 
Depletion of TbTEL2 resulted in a growth defect 
 Dr. George Cross from the Rockefeller University identified a putative TbTEl2. 
The identification was established by the alignment of several published TEL2 sequences 
including TEL2 in budding yeast (Runge and Zakian 1996), TEL2 in S. pombe (Hayashi 
et al. 2007), human TEL2 (Takai et al. 2007) and TEL2 homolog in C. elegans (Ahmed 
et al., 2001) with putative TbTEL2, which indicated a sequence similarity that is not 
highly conserved, yet was similar enough so we named it TbTEL2.   
In order to deplete TbTEL2, we generated a strain harboring a single allele of 
TbTEL2, where the other allele was replaced with the blasticidin marker (TbTEL2 +/-). 
An inducible TbTEL2 RNAi construct was targeted into the rDNA locus. To deplete 
TbTEL2, a dsRNA was generated under the Tet operon regulated T7 promoter, where the 
Tet repressor bound to the Tet operon in the absence of doxycyclin, thereby inhibiting 
transcription of TbTEL2 dsRNA. When doxcyclin was added, it bound to the Tet 
repressor, thereby allowing T7 transcription of TbTEL2 dsRNA. The generation of 
dsRNA targets TbTEL2 to the RNAi pathway of degradation. 
  Upon induction of TbTEL2 dsRNA with 100 ng/ml of doxycycline, a transient 
growth arrest was observed followed by a slow recovery in clone C6 (Figure: 5-1a). In 
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contrast, a growth arrest was observed for clones A7 and A8 (Figure: 5-1c). For clone C6, 
the growth curve was more carefully characterized compared to clones A7 and A9, where 
only days 0, 2, 4 and 6 were analyzed. The following time points were carried out for 
clone C6: days 0, 1, 2, 3, 4 and 5. It is possible that slow recovery cannot be captured 
from spread out time-points. Only clone C6 harbors a tagged allele of TbTEL2 (F2H-
TbTEL2) and a Western blot analysis was performed to confirm the depletion of TbTEL2 
(Figure 5-1b). 
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 Figure 5-1: Growth curve analysis upon the depletion of TbTEL2. (A) RNAi 
induction for TbTEL2 was carried out in a single knockout background; clone C6 was 
analyzed from day 0 to day 5. Transient growth arrest with slow growth recovery was 
observed. (B) Western analysis for the depletion of TbTEL2. TbTEL2 was not detected 
after 48 hours. 12CA5 antibody was used to detect F2H-TbTEL2; tubulin was used as a 
loading control. (C) Additional RNAi induction for TbTEL2 was performed in a single 
knockout background. Clones A7 and A9 were analyzed at day 0, 2, 4 and 6 after 
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depletion of TbTEL2. Complete growth arrest was observed in these clones. The arrest 
occurred within 24 hours.  
 
Depletion of TbTEL2 led to decrease in G-overhang signal 
In Saccharomyces cerevisiae, Tel2 is important for telomere length maintenance, 
(Lustig and Petes 1986) and telomere position effect (Runge and Zakian 1996), where a 
tel2-1 mutation reduced telomere position effect. In light of these findings, we questioned 
if TbTEL2 played any role in telomere homoeostasis in T. brucei. Characterization of G-
overhang signal, in the presence or absence of TbTEL2, illustrated that indeed, TbTEL2 
is important for G-overhang maintenance. G-overhang signal was reduced gradually 
suggesting that the affect of TbTEL2 is additive. Within 48 hours of TbTEL2 depletion, 
G-overhang signal was reduced to ~ %80 (Figure: 5-2). 
Although mammalian TEL2 does not have any obvious telomeric functions 
(Takai et al. 2007), it seems that TbTEL2 resembles ScTel2 in its telomeric phenotype.  It 
is too premature to make any conclusions about TbTEL2’s role in telomere protection, 
but preliminary data suggests that TbTEL2 is important for telomere homoeostasis. 
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Figure 5-2: Depletion of TbTEL2 leads to a decrease of G-overhang signal. (A) In-
gel hybridization of TbTEL2 plugs prepared at 0 hours, 48 hours after induction and 72 
hours after induction. The native gel was used to determine the G-overhang signal that is 
normalized against the total DNA (denatured gel) (B) Quantification of G-overhang 
signal from native and denatured gels (consult Appendix A for calculation). 
 
TbTEL2 affected the stability of TbTOR1  
 Mammalian Tel2 was shown to be important for the protein stability of the PI3-
related kinases but not their mRNA levels (Takai et al. 2007;!Chang and Lingner 2008). 
To test the possibility that TbTEL2 affects the stability of PI3-related kinases, several 
putative PI3-kinases were tagged: TbTOR1 (Tb10.6k15.2060), TbTOR2 (Tb927.4.420) 
and ATM (Tb11.01.6300). Only TbTOR1 was successfully tagged in the previously 
described single knockout and RNAi TbTEL2 cells. Several tries to obtain F2H-TbTOR2 
and F2H-ATM were not successful in TbTEL2 -/+ only. We did not try to tag these in 
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TbTEL2 +/+ background. TbTOR1 was detected with anti-F2H antibody: 12CA5. 
Protein samples were collected to assess the stability of TbTOR1 upon the depletion of 
TbTEL2 at 24 and 48 hours. TbTOR1 protein levels decreased upon the depletion of 
TbTEL2 (Figure: 5-3a). However, the depletion of TbTEL2 did not affect the protein 
levels of TbTRF (Figure: 5-3b). 
 
 
Figure 5-3: Western blot analysis of TbTOR1 and TbTRF protein levels upon the 
depletion of TbTEL2. (A) TbTOR1 protein level decreased dramatically upon the 
depletion of TbTEL2. (B) TbTRF protein level was not affected. Tubulin was used as a 
loading control.  
 
 
 
 
 
 
! 96 
TbTEL2 is important for VSG switching 
 VSG switching is regulated by several factors including telomere length (Hovel-
Miner et al. 2012), DNA recombination (McCulloch and Barry 1999; Proudfoot and 
McCulloch 2005; Kim and Cross 2010;! Kim and Cross 2011) and DNA replication 
(Benmerzouga et al. 2013). In addition, ScTel2 was shown to be important for TPE 
(Runge and Zakian 1996), a phenomenon that has been shown to be critical for VSG 
silencing (Yang et al. 2009). Therefore, we questioned whether TbTEL2 played any role 
in antigenic variation.  
 We tested the expression of several silent VSGs upon the depletion of TbTEL2: 
VSG9 and VSG13 (Figure: 5-4a). Upon the depletion of TbTEL2 we observed the 
expression of VSG9 but not VSG13, suggesting that there may be a switching 
phenomenon that is taking place (Figure: 5-4a). In order to address this question, a 
TbTEL2 RNAi construct was introduced into the HSTB261 strain (the doubly marked 
reporter strain). Only one switching assay was performed as a screen for the potential role 
of TbTEL2 in VSG switching regulation. TbTEL2 RNAi cells did not arrest as 
dramatically as in a single knockout background (compare to Figure: 5-1). Instead, they 
had a slower growth phenotype (Figure: 5-4b). We depleted TbTEL2 for 72 hours prior 
to conducting the switching assays. On the other hand, the VSG switching assay was 
performed for cells without induction as a control. Indeed, upon the depletion of 
TbTEL2, VSG switching frequency increased by ~ 6 fold. 
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Figure 5-4: Depletion of TbTEL2 led to increase in VSG switching frequency. (A) 
Western blot analysis of silent VSG9 upon the depletion of TbTEL2. In addition, 
TbTEL2 depletion did not affect TbTRF protein levels. (B) Growth analysis of 
HSTB261-TbTEL2-RNAi clones B6 and B12. Slow growth was observed upon TbTEL2 
depletion. (C) Depletion of TbTEL2 results in an increase in VSG switching frequency.  
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DISCUSSION  
Tel2 was first identified in budding yeast as a negative telomere length regulator 
(Lustig and Petes 1986). Further studies were done to characterize the role of ScTel2 and 
studies showed that ScTel2 is essential for cell viability, telomere position effect and 
telomere homeostasis (Runge and Zakian 1996). In addition, studies in budding yeast 
have shown that Tel2 binds telomeric DNA (Kota and Runge 1998; Kota and Runge 
1999). In Schizosaccharoyces pombe, Tel2 was shown to physically interact with all the 
phosphoinositide 3-kinase- related kinases (PIKKs) (Hayashi et al. 2007). In 
Caenorhabditis elegans, clk-2 (a budding yeast tel2 homolog) was critical for telomere 
homeostasis (Benard et al. 2001). In mammalian cells, Tel2 was shown to be important 
for embryonic stem cell viability and to affect the stability of all six PI3-related kinases 
(Takai et al. 2007).  
In T. brucei, a protozoan parasite that causes human sleeping sickness disease, a 
putative TbTEL2 homolog was identified through an in silico approach. However, 
TbTEL2 was not characterized and to date nothing is really known about TbTEL2. Since 
budding yeast Tel2 and C. elegans clk-2 were shown to be important for telomere length 
regulation, we speculated that TbTEL2 might play a role in telomere homeostasis. To test 
this, we analyzed the G-overhang signal upon the depletion of TbTEL2 and we observed 
a substantial decrease in G-overhang signal, suggesting that TbTEL2 plays a role in 
telomere homeostasis. Further experiments need to be done to support this hypothesis. 
PIKKs are key signal transducers that function in multiple pathways. They are 
involved in DNA repair, cell cycle arrest, cell cycle progression and cell cycle 
checkpoints. There are 6 known mammalian PIKKs: Ataxia telagiectasia mutated (ATM), 
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ATM and Rad3 related (ATR), DNA-dependent protein kinase catalytic subunit ataxia 
(DNA-Pkcs), Mammalian target of rapamycin (mTOR), Suppressor with morphological 
effect on genitalia 1 (SMG1) and transformation/transcription domain-associated protein 
(TRRAP). Mammalian Tel2 affects the stability of all six PI3-related kinases (Takai et al. 
2007). We tested the potential role of TbTEL2 in the stability of known PI3-kinases by 
tagging TbTOR1, TbTOR2 and Tb6300 (a possible ATM homolog); only TbTOR1 was 
successfully tagged and used for the screen. Tagging of TbTOR2 and Tb6300 should be 
carried out in a wild-type background to test for the possibility that a single allele of 
TbTEL2 hindered their tagging with F2H tag.  
If TbTEL2 affects the stability of TbTOR1, we expect that upon the depletion of 
TbTEL2, TbTOR1 protein levels will substantially decrease. Indeed, upon the depletion 
of TbTEL2, and within 24 hours, TbTOR1 protein levels decrease dramatically compared 
to TbTOR1 levels in the presence of TbTEL2. This suggests that TbTEL2, like 
mammalian Tel2, plays a role in the stability of PI3-related kinases. Further experiments 
should test the stability of TbTOR2 and Tb6300 and the mRNA levels of TbTOR1, 
TbTOR2 and Tb6300 upon the depletion of TbTEL2. These experiments must be 
conducted in order to substantialize this conclusion.  
Finally, one of the most interesting aspects of T. brucei is how it regulates mono-
allelic expression and VSG switching. Several factors have been described that regulate 
either mono-allelic expression or VSG switching or both. Since TbTEL2 might play a role 
in telomere homeostasis, and telomeric proteins have been reported to play an essential 
role in VSG regulation, we investigated if TbTEL2 played a role in antigenic variation. A 
Western blot analysis for the expression of multiple silent VSGs at one time is a standard 
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indication of a VSG derepression phenotype. Upon the depletion of TbTEL2, silent VSG9 
and VSG13 protein levels were analyzed, in addition to the originally active VSG2. Only 
the expression of VSG9 was observed but not VSG13, suggesting that it is not a de-
repression phenotype that was observed, rather a VSG switching phenotype. To address 
this, we introduced TbTEL2-RNAi vector into the HSTB261 reporter strain. Upon the 
depletion of TbTEL2, we observed an increase in VSG switching frequency, in agreement 
with our hypothesis. However, additional switching assays must be performed and 
detailed analysis of VSG switching mechanisms must be characterized in order to solidify 
this conclusion. 
In summary, the putative TbTEL2 phenotypes indicate that indeed, this may be 
the TEL2 homolog in T. brucei. Further experiments need to elucidate if TbTEL2 
associates with the telomere or not, if TbTEL2 binds dsDNA or ssDNA as is the case in 
budding yeast (Runge and Zakian 1996) and if TbTEL2 affects telomere length. These 
studies are needed in order to firmly conclude that the putative TbTEL2 is indeed 
TbTEL2. Constructs for these studies have been prepared and are in the laboratory lab 
plasmid stock. Successful expression of TbTEL2 is needed to conduct gel shift 
experiments to test TbTEL2’s binding to telomere DNA.  !
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CHAPTER VI 
PRELIMINARY DATA FOR FUTURE STUDIES 
Imaan Benmerzouga 
Trypanosoma brucei Origin Recognition Complex 1 (TbORC1) 
Origin Recognition Complex, a critical DNA replication initiation complex, has 
been thoroughly studied in yeast and mammals. Although, it is not well conserved in T. 
brucei, components of the ORC complex exist in T. brucei such as Orc1, Orc4, Orc1-like 
protein or Orc1b and couple of other novel ORC components that are yet not classified 
(Godoy et al. 2009; Dang and Li 2011; Tiengwe et al. 2012b). Among these components, 
TbORC1 was reported to affect antigenic variation in two independent studies and 
collectively, the function of TbORC1 in antigenic variation was found across all life 
stages of T. brucei (Tiengwe et al. 2012a; Benmerzouga et al. 2013). 
 In yeast, ORC1 possesses the nucleosome binding BAH domain that interacts 
with key silencers to form the heterochromain at telomeres (Hickman and Rusche 2010). 
TbORC1 lacks the BAH domain (Tiengwe et al. 2012b) suggesting functional differences 
in TbORC1. In addition, TbORC1 does not interact with TbRAP1 (Benmerzouga et al. 
2013), a major silencer in T. brucei (Yang et al. 2009) suggesting that TbORC1 plays an 
independent role in VSG silencing.  
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ORC associates with heterochromain protein 1 (HP1), an important component of 
tightly packed telomeres and centromeres in Drosophila (Huang et al. 1998) and this 
interaction mediates heterochromatin induced silencing (Shareef et al. 2001). Therefore, 
it is possible that TbORC1 regulates VSG silencing via heterochromatin and through a 
direct interaction with a homologue of HP1. To date, there are no homologues of HP1 in 
T. brucei but sequence alignments suggest the presence of the chromosome organization 
modifier) or chromo domain in histone acetyltransferases HAT-1 and HAT-2 that are 
analogous to the chromo domain present in HP1 (Kawahara et al. 2008). Depletion of 
HAT-1 affected telomeric silencing but not VSG expression and is essential for cell 
growth (Kawahara et al. 2008). HAT-1 knockdown cells proceed to mitosis without 
nuclear DNA replication, suggesting an impaired DNA replication progression. 
Therefore, it is possible that TbORC1 and TbHAT-1 directly interact at heterochromatin 
regions for both silencing and replication progression. Direct interaction studies must be 
carried out for both proteins and the localization of TbORC1 upon the depletion of HAT-
1 and the localization of HAT-1 upon the depletion of TbORC1 would provide insights to 
whether TbORC1 affects heterochromatin and if so, whether heterochromatin 
organization is mediated via a chromo domain containing protein in T. brucei HAT-1, a 
function that has been observed in higher eukaryotes (Pak et al. 1997). 
Our study did not report any changes in heterochromatin status (Benmerzouga et 
al. 2013) and the analysis of derepression at the promoter (Figure: 6-1) failed to provide 
an explanation for the derepression phenotype of sub-telomeric VSGs. However, the 
promoter is 40-60 kb upstream of VSG and hence TbORC1’s effect is exclusively at sub-
telomeres.  
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A recent study by Deng et al. (2009) showed that TERRA (telomere repeat 
containing RNA), TRF2 and ORC1 form a ternary complex at telomeres, which is crucial 
for heterochromatin formation. Attempts to study the expression of TelRNA or TERRA 
in TbORC1 depleted cells and preliminary data suggest that the depletion of TbORC1 
resulted affect TERRA transcripts (data not shown), however, optimization of the 
protocol to detect TERRA must be established prior to making any conclusive results. 
Therefore, it is possible that TbORC1 may affect TERRA in T. brucei and hence 
TbORC1 association at telomeres, which is a mechanism whereby TbORC1 affects VSG 
silencing. Future experiments should test this possibility.  
 
Figure 6-1: No changes in the transcription of PURO reporter gene upon the 
depletion of TbORC1. (A) Schematic representation of the strain utilized for promoter 
analysis study. Silent VSG2 ES promoter site is tagged with PURO gene. Any 
derepression of silent VSG2 promoter can be detected by the amplification of PURO from 
cDNA. (B) Quantification of PURO expression changes with and without TbORC1. D0 
expression is set arbitrary at 1 and any changes to the transcription of PURO is 
normalized against D0.  
 
Studies on ORC complex in T. brucei will provide insights into the role of 
replication at sub-telomeres, which affects VSG silencing. These findings can be utilized 
along with other telomere silencing factors to eliminate T. brucei and other fatal parasites 
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that use telomereic silencing to regulate antigenic variation to escape the host immune 
system (Li 2012).  
Trypanosoma brucei TTAGGG Repeat Binding Factor (TbTRF)  
Although not all the shelterin complex proteins have been identified in T. brucei, 
the two identified proteins exhibit effects on antigenic variation (Yang et al. 2009; 
chapter IV). Homologue of TRF2 in T. brucei was identified by Li et al. (2005) and 
TbTRF lacks the acidic or basic domain present in mammalian TRF1 and TRF2 
respectively and constitutes of only two domains: TRFH domain and MYB domain, both 
the TRFH domain and MYB domain are required for TRF telomere DNA binding 
activity. TbTRF MYB domain structure is composed of three helices making a helix-
turn-helix motif. Like mammalian TRF1 and TRF2 (Hanaoka et al. 2005), the third helix 
recognizes telomeric DNA. Domain interaction and domain functional studies have been 
extensively dissected for hTRF1 and hTRF2 (for review, see Diotti and Loayza 2011). 
However, there are no reported roles for TbTRF MYB domain or TRFH domain.  
To date, studies that reported regulation of antigenic variation through regulating 
VSG switching were 1) telomere length (Hovel-Miner et al. 2012), 2) DNA replication 
(Benmerzouga et al. 2013) and 3) DNA recombination factors (Kim and Cross 2010), 
(Kim and Cross 2011). Therefore, if TbTRF affects VSG switching, telomeric proteins 
will be an additional factor that regulates VSG switching.  
 
Trypanosoma brucei TTAGGG Repeat Binding Factor (TbTRF) and G-overhang 
Telomeres end with a G-rich single stranded DNA (Wellinger and Sen 1997). A 
specialized structure known as a T-loop, where the G-rich strand invades the double 
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stranded telomere ends making a loop, sequesters the single stranded DNA end from 
being recognized as Double Strand Breaks (DSBs) (Murti and Prescott 1999). T-loops are 
detected in T. brucei nevertheless, they are smaller in size ~ 1 kb compared to 
mammalian T-loops which can be ~ 25 kb (Munoz-Jordan et al. 2001).  TRF2 protects 
telomeres from end to end fusions (van Steensel et al. 1998). TRF2 binding to the 
proximity of 3`-overhang is required for the assembly of the T-loop in vitro (Stansel et al. 
2001). TbTRF resembles mammalian TRF2, for its depletion resulted in the loss of G-
overhang signal. If T-loops are a conserved structure to protect telomeres and are 
stimulated by TRF2 binding towards the telomere end, close to 3`-G-overhang, then the 
DNA binding activity of TRF2 is indeed an important regulator of this function. T-loop 
studies utilizing the telomere-binding mutants will solidify the mechanistic formation of 
T-loops at chromosome ends in T. brucei as well as the role of TbTRF DNA binding 
activity in G-overhang maintenance. After prolonged attempts, the preliminary data 
suggest that not all the DNA binding mutants affect G-overhang signal (Figure: 6-2). 
Further G-overhang analysis should be carried out for each mutant, although highly 
discouraged due to the significant variation in the results. The application of a more 
sensitive assay is needed to characterize the differences in G-overhang length among the 
mutants. The standardization of such an assay is on-going in the lab. 
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Figure 6-2: G-overhang analysis in TbTRF mutants. Mutants were grown for 13 
weeks and analyzed for G-overhang signal compared to WT. (A) C-strand hybridized gel 
to show G-overhang (B) G-strand hybridized control gel to show the specificity of the C-
strand gel signal (C) Quantification of (a) G overhang signal. Probes used are indicated 
on top. 
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Characterization of TbTRF and TbRAP1 interaction in vitro 
TbRAP1 is an integral telomeric component that plays an essential role in VSG 
silencing. Our studies have suggested that TbRAP1 depends on TbTRF to be targeted to 
telomeres, which is critical for its function. In addition, changes in this interaction may 
influence VSG switching. Therefore, the interaction of TbRAP1 with TbTRF mutants was 
characterized in vitro using yeast-two-hybrid analysis. Since TbRAP1 interacts with the 
MYB domain of TbTRF directly, the characterization was dissected into the interaction 
with full-length TbTRF and the interaction with the MYB domain only.  
For TbTRF-R348K and TbTRF-Q320S, yeast-two-hybrid analysis was carried out 
for 9 independent clones from 3 independent transformations. The interactions were 
averaged and plotted and a standard deviation was determined. TbRAP1 interaction with 
the MYB domain of TbTRF-R348K mutant was significantly affected (Figure: 6-3a), 
however, when the interaction was characterized with full-length TbTRF harboring 
R348K as a point mutation, the over-all interaction with TbRAP1 did not change 
significantly (Figure: 6-3b). Therefore, it is unlikely that the weakened TbRAP1 
interaction with TbTRF MYB domain can be recapitulated in vivo using Co-IP, due to 
insignificant changes in the overall interaction in vitro.  
For TbTRF-R298K and TbTRF- H346R, the interaction of TbRAP1 with the 
MYB domain of the mutants did not differ significantly (Figure: 6-4a). In addition, the 
overall interaction with TbRAP1 was not affected (Figure: 6-4b). This illustrates that 
TbTRF mutants do not affect TbRAP1’s interaction with TbTRF. Therefore we presume 
that the role of TbTRF in antigenic variation is independent of TbRAP1 and therefore, no 
future work is encouraged. 
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Figure 6-3: Yeast-two hybrid analysis of the interaction of TbTRF-R348K or 
TbTRF-Q320S with TbRAP1. (A) Interaction of the MYB domain only of TbTRF-
R348K or TbTRF-Q320S mutant with TbRAP1. TbTRF-R348K had significantly weaker 
interaction with TbRAP1. No significant changes were observed in TbRAP1’s interaction 
with TbTRF-Q320S. (B) Interaction of full-length TbTRF-R348K mutant with TbRAP1 
or TbTRF-Q320S with TbRAP1. No significant changes were observed. Overall, the 
interaction of TbRAP1 with TbTRF-R348K or TbTRF-Q320S was not affected.  
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Figure 6-4: Yeast-two hybrid analysis of the interaction of TbTRF-R298K or 
TbTRF H346R with TbRAP1.  (A) Interaction of the MYB domain only of TbTRF-
R298K or TbTRF-H346R mutants with TbRAP1. No significant changes were observed 
in the interaction of TbRAP1 with TbTRF mutants compared to wild-type TbTRF. (B) 
Interaction of full-length TbTRF-R298K or TbTRF-H346R mutants with TbRAP1. No 
significant changes were observed in the interaction of TbRAP1 with TbTRF mutants 
compared to wild-type TbTRF.  
 
TbRAP1 recruitment to telomeres in TbTRF mutant 
To determine if weakened DNA binding activity of TbTRF affects the recruitment 
of TbRAP1 to telomeres, we performed ChIP analysis of TbRAP1 in a wild-type 
background and in the background of TbTRF -/R348K mutant. We do notice the increase 
of TbRAP1 at telomeres in TbTRF -/R348K, however careful analysis must be carried 
out in order to make such a conclusion. It is possible that TbRAP1 is recruited more to 
telomeres due to the changes in TbTRF binding to telomeres (Figure: 6-5). However, as a 
control to the recruitment of TbRAP1 to telomeres in TbTRF -/R348K, ChIP of TbRAP1 
in a single knockout background of TbTRF is required to tell us if this phenotype is 
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because of the mutation itself or because of knocking out a single allele of TbTRF. In 
addition, ChIP analysis of TbTRF -/R348K must be carried out to determine how much 
TbTRF is at the telomeres in this particular mutation in vivo.   
 
Figure 6-5: ChIP analysis of TbRAP1 at telomeres. We analyzed the recruitment of 
TbRAP1 in TbTRF wild-type background and in TbTRF -/R348K mutant. We observe a 
significant increase in TbRAP1 recruitment to telomeres in the TbTRF -/R348K mutant. 
(A) Quantification of 3 independent ChIPs for TbRAP1 in wild-type and in TbTRF -
/R348K backgrounds, respectively. (B) Representative slot blots used to quantify 
TbRAP1’s binding to TTAGGG.  
 
TbTRF and VSG switching 
 
VSG switching analysis was performed upon the depletion of TbTRF. Two sets of 
experiments were performed, VSG switching assays without induction and VSG 
switching assays with induction (Figure 6-6). For each clone, at least 7 experiments were 
carried out for the transient depletion of TbTRF and at least 3 experiments were carried 
out without any induction. Cells were induced for 24 hours with 200 ng/ml doxycycline 
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and recovered by the removal of doxycycline though several washes with media. In both 
cases, cells were allowed to undergo the same population doublings and the same 
washing conditions. HSTB261-TbTRF-RNAi without induction recovered a day prior to 
HSTB261-TbTRF-RNAi with induction. Switching frequencies were calculated as 
described (see chapter II). TbTRF depletion resulted in a significant (~ 5-10 fold) 
increase in VSG switching frequency in all four clones as illustrated in (Figure: 6-7).  
 
 
Figure 6-6: Diagram of TbTRF-RNAi method in preparation for the switching 
assay. Cells were induced or un-induced for 24 hours. After 24 hours, cells were washed 
with media lacking selective drugs (see chapter II). When cells reached the same 
population doublings, the switching assay was performed for both induced and un-
induced cells (see chapter II). 
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Figure 6-7: VSG switching frequency upon the transient depletion of TbTRF. 
Switching assays were performed for all four clones established and confirmed for the 
transient depletion of TbTRF as described in chapter IV. Preliminary data suggest that 
there is a significant increase in VSG switching frequency in clones A7, A8, B1 and B2 
upon the transient depletion of TbTRF for 24 hours. 
 
 These data suggest that the transient depletion of TbTRF affects VSG switching 
frequency. These data need to be further validated. Since telomere length affects VSG 
switching frequency (Hovel-Miner et al. 2012), it is strongly suggested that telomere 
length is examined upon the transient depletion of TbTRF. Although no changes in 
telomere length were observed upon the depletion of TbTRF (Li et al. 2005), it is 
possible to detect these changes upon the transient depletion of TbTRF, which was not 
performed by Li et al. (2005). These experiments are needed, primarily to detect if the 
transient depletion of TbTRF affects VSG switching frequency, and if so, it is essential to 
determine if telomere length is affected upon the transient depletion of TbTRF. If 
telomere length is affected, then the changes in VSG switching frequency observed upon 
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the transient depletion of TbTRF is a consequence of changes in telomere length. Future 
experiments will provide insights into these possibilities.   
TbTRF MYB domain mutants and VSG switching 
 
We investigated if the expression of VSG13 in TbTRF -/R348K was due to VSG 
switching events. To do so, these point mutations were introduced into a reporter strain to 
study VSG switching frequency. Also, we performed switching assays in TbTRF -/+ cells 
to control for the possibility that the deletion of a single allele of TbTRF resulted in VSG 
switching frequency changes. If VSG switching frequency increased in TbTRF -/+ cells, 
then a single knockout allele of TbTRF is affecting the VSG switching frequency and not 
the introduced point mutations. For each mutant, at least two different clones were tested 
and for each clone, the assay was carried out multiple times (4-7 assays per clone). 
Clones from the same mutant showed comparable changes in the switching frequency, 
allowing us to pool the switching frequency changes into one bar representing the 
average of both clones from one mutant, therefore at least 8-14 assays are presented per 
bar.  
An unpaired t-test was used to determine the P-values of the VSG switching 
frequency changes. In the unpaired t-test, the resulting frequencies from TbTRF -/R298K, 
TbTRF -/Q320S, TbTRF -/H346R, TbTRF -/R348K and TbTRF -/+ were compared to 
the wild-type switching frequency.  P-values are indicated on each bar (Figure 6-8).  
The highest average of switching frequency was observed in TbTRF -/H346R 
with ~ 4.45 x10^-5 events/cell generation. Switching assays for TbTRF -/Q320S were 
performed in the same fashion and no increase in VSG switching frequency was 
observed. Finally, we also performed switching assays in wild-type cells having both 
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alleles of TbTRF (TbTRF +/+) and in the parental cells having one allele of TbTRF 
(TbTRF -/+). We did not observe any significant changes in previously reported wild-
type switching frequency (Kim and Cross 2010) in both TbTRF +/+ cells and TbTRF +/- 
cells. In addition, the difference in the switching frequency of TbTRF -/+ from TbTRF 
+/+ cells was not significant. The latter supports that the changes in switching frequency 
observed in the TbTRF DNA binding mutants R298K, H346R and R348K were not a 
consequence of the knockout of an allele of TbTRF (Figure 6-8). 
 
 
Figure 6-8: VSG switching frequency in TbTRF mutants. Preliminary data suggest 
that some TbTRF MYB domain mutants showed on average a 3-fold increase in VSG 
switching frequency. No increase in VSG switching frequency was observed in TbTRF -
/Q320S. There were no significant changes in the VSG switching frequency in parental 
cells (TbTRF -/+). Each bar represents an average of at least 14 experiments from 2 
independent clones per mutant, except switching assays performed for TbTRF -/+ where 
only 6 assays were performed. Each bar was compared to TbTRF +/+ switching 
frequency in an unpaired t-test. P-values are indicated on bars.  
! 115 
These observations suggest that TbTRF MYB domain mutants affect VSG 
switching frequency. Nevertheless, further assays must be carried out to validate these 
observations. In addition, future experiments must analyze the VSG switching frequency 
in the remaining mutants Q321S and R352K in order to support our hypothesis that the 
DNA binding domain of TbTRF affects VSG switching frequency.  However, the 
question remains to as why not all DNA binding mutants affected VSG switching 
frequency.  
 These differences cannot be explained from the in vitro DNA binding studies, 
because the Kd value for TbTRF-MYB-H346R is lower than the Kd value for TbTRF-
MYB-Q320S, making TbTRF-MYB-Q320S a stronger mutant. Nevertheless, we did not 
observe any changes in VSG switching frequency in TbTRF -/Q320S strain. It is possible 
that the DNA binding activity of TbTRF -./Q320S is not affected in vivo. However, ChIP 
analysis must be performed in order to test this hypothesis. In addition, it is possible that 
the telomere length in the TbTRF -/R298K, TbTRF -/H346R and TbTRF -/R348K is 
affected but not in the TbTRF -/Q320S and hence we do not observe changes in VSG 
switching frequency in the TbTRF -/Q320S. These experiments will explain the 
differences observed in the VSG switching frequency among the TbTRF mutants. 
 
TbTRF binding to telomeres in the absence of J in vivo 
As describe in chapter IV, we successfully established cells where J was depleted. 
However, only three ChIP experiments were performed. ChIP was performed after 
treating the cells with DMOG for 6 days at a 0.5 mM or with DMSO in the same manner 
and for the same time length or without any treatment grown for the same time length.  
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Figure 6-9: ChIP of TbTRF in the presence or absence of J-base. (A) ChIP analysis 
of TbTRF binding to telomere DNA in the presence (wild-type and DMSO treatment) or 
absence of J (DMOG treatment). At least three independent ChIPs were performed. An 
un-paired t-test was used to determine the significance of the changes. No significant 
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changes were observed in TbTRF association with telomere DNA in the presence or 
absence of J. (B) Quantification and representative slot blot of 50bp repeats 
hybridization. These data were generated for binding specificity control. 
 
 ChIP products were normalized against input to obtain the percent of enrichment 
(see appendix A for details). To date, there were no significant changes in the binding of 
TbTRF to telomeres in the absence of J (Figure: 6-9a). As a control to the specificity of 
binding, blots were hybridized with 50bp repeats. No binding was detected in any 
scenario, validating that TbTRF specifically pulls down telomeric DNA and not any other 
sequence (Figure 6-9b). Further ChIPs must be carried out in order to firmly conclude 
that the binding of TbTRF to telomeres is not affected by the presence of J in vivo.  
 
TbTRF mutants, VSG switching and mouse studies 
If TbTRF affects VSG switching and if this effect is a consequence of TbTRF’s 
DNA binding activity, then the TbTRF DNA binding mutant will be a unique tool to 
investigate the consequence of targeting VSG switching in mouse models. Whether T. 
brucei manages to escape host immune detection despite the elevation in VSG switching 
frequency, or whether targeting VSG switching allows the host’s immune system to 
effectively eliminate T. brucei, these mutants and other studies that characterized VSG 
switching changes will provide insights to whether targeting VSG switching is indeed a 
therapeutic intervention.   
Finally, these mutants will provide answers to a long-term hypothesis that 
telomere proteins play an important role in the pathogenesis of not only T. brucei, but 
also other parasites that utilize antigenic variation. These mutants provide a direct 
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measure to investments in therapeutic discovery and targeting the telomeric proteins of 
parasites as a mean to eliminate T. brucei and other parasites.  
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APPENDIX A 
 
 
EQUATION USED TO CALCULATE mRNA FOLD CHANGES IN Q-RT-PCR 
 
mRNA fold change = (mRNAV, n/mRNAV, 0)/(mRNAT, n/mRNAT, o), where 
(mRNAV, n) and (mRNAV, 0) represent the mRNA level for a particular VSG in the n hr 
and 0 hr, and mRNAT, n and mRNAT, 0 represent the mRNA levels for $-tubulin at 
corresponding time points. 
 
EQUATION UTILIZED TO CALCULATE B-GALACTOSIDASE ACTIVITY 
Miller Units = (1000 x OD420) /TxVx OD600 
Where T = time of the reaction in minutes. 
           V= Volume of culture used in the assay. 
           OD600= Cell density in the cell suspension. 
 
EQUATION USED FOR  ChIP PERCENTAGE OF ENRICHMENT CALCULATION  
Percentage of enrichment = (IP product/33.3x106)/(Input/1.6x106) x 100 %. (33.3x106 and 
1.6x106 are the total number of cells per sample).  
Approximately 100 million cells are used per ChIP, where the 100 million cells are re-
suspended in 300 µl of lysis buffer. The lysate is divided into 3 tubes, the first tube is the 
input, the second tube is sample to be precipitated without an antibody (No Ab sample) 
and the third tube is the actual pull-down experiment (Ab sample). For the actual ChIP 
samples, (No Ab and Ab samples), 100 µl of the lysate is used to do the pull-down 
experiments. Therefore, 1/3 of the sample is used for both the No Ab and the Ab 
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experiments. Therefore the total number of cells used for both the No Ab and the Ab 
sample is 100 x106 cells/3 = 33.3 x106  cells. The samples are not further diluted. For the 
input sample, only 25 µl of sample is taken out from the lysate, which corresponds to 
1/12 of the sample. The sample is further diluted (1:5) dilution; this step is to ensure that 
the resulting intensity from the input is legible. Therefore the total number of cells used 
for the input = 100 x106 cells x 1/60 = 1.6 x106 cells. (Note: input sample is always highly 
enriched so either 5 µl of sample is taken out of the lysate or diluting the input sample if a 
large volume is taken out- in this case 25µl- either way will not change the final cell 
number of 1.6 x106 cells). Then the intensity of the signal obtained from the slot blot for 
the corresponding sample is divided by the total number of cells used, as detailed above. 
Finally, the percent of enrichment is determined by dividing the IP product result over the 
input. 
  
EQUATION USED TO CALCULATE POPULATION DOUBLING FOR GROWTH 
ANALYSIS 
Population doubling = log2 (total number of cell, n/total number cells, (n-1)) + PD (n-1), 
where n is hour or day time point and n-1 is the immediate time-point preceding n. 
 
EQUATION USED TO CALCULATE G-OVERHANG SIGNAL 
Raw G-overhang signal =  (Native TelC4 signal)/ (Denatured TelC4 signal) 
Normalized G-overhang signal = Raw G-overhang signal/ Raw G-overhang signal of 
WT. 
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APPENDEX B 
PRIMERS USED IN THESE STUDIES 
Primer 
number  
Primer Sequence 
1 OIB-tbORC1-5`-UTR-FW-XhoI GCGCTCGAGGTTCGTTGAGCA
GTTGGG 
2 OIB-tbORC1-5`-UTR-BW-RI GCGGAATTCGGCACCTGCTAA
AACCC 
3 OIB-TbORC1-3`-UTR-FW-XbaI GCGTCTAGATTGTAAAATACC
GTCTTAGGACG 
4 OIB-tbORC1-3`UTR-BW-NotI GCGGCGGCCGCTCTCCAGTCC
CCCTCATT 
5 OIB-tbOrc1-star-FW-BamHI GGATCCTGAAACGAAGGAGGG
ACA 
6 OIB-TbOrc1-end-BW-SaII GCGGTCGACCTATATCGAAAA
CAGTGGGC 
7 OBL-tbORC1-end-RI GCGGAATTCCTATATCGAAAC
AGTGGGC 
8 OBL-tbORC1-start-RI 
 
GCGGAATTCATGAAACG 
AAGGAGGGAC 
9 OBL-tbORC1-end-BamHI GCGGGATCCCTATATCGAAAA
CAGTGGGC 
10 OBL-tbTRF-start-H3 GCGAAGCTTTACTGTCACGCT
GGCG 
11 OBL-tbTRF-myb-start(longFW) AACTTTGCTAATGTGGGCG 
12 OBL-tbTRF-myb-start(longBW) 
 
CGCCCACATTAGCAAAGTT 
13 OBL-tbTRF-END-SpeI 
 
GCGACTAGTTCACTCGTTATTC
TCCATATTG 
14 OBL-tbTRF-2H-Start-BamHI 
 
GCGGGATCCACTGTCACGCTG
GCGTT 
15 OBL-tbTRF-2H-5myb-FW-BamHI 
 
GCGGGATCCGGACATCATCCG
GCAAG 
16 OBL-tbTRF-end-BW-PstI 
 
GCGTGCAGCTCACTG 
TTATTCTCCATATTGG 
17 OBL-BSD-FW1 
 
CCAAGCCTTTGTCTCAAGA 
18 OBL-BSD-end-BW1 
 
TTAGCCCTCCCACACATAA 
19 OBL-VSG221-FW1 
 
GTCCTAGCCCAAGTTCTTC 
20 OBL-VSG221-BW1 
 
GCTGTTGCAGTAGCTGTTAC 
21 OBL-splice leader –FW-new GACTAGTTTCTGTACTATAT 
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22 OBL-VSG-common-BW-new GACTAGTGTTAAAATATATCA 
23 OIB- tbTOR1-5UTR-FW-Sal 
 
GCGGTCGACAGCTGGGTTGTG
CTCAGA 
24 OIB- tbTOR1-5UTR-BW-RI 
 
GCGGAATTCATGTCACTGCCC
CCC  
25 OIB-tbTOR1-NT-FW-XbaI 
 
GCGTCTAGATGCGCCCATCCG
TTAACA  
26 OIB-tbTOR1-NT-BW-NotI 
 
GCGCGCGGCCGCGCACGCAGC
AACCTTATC  
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APPENDEX C 
PLASMID GENERATED FROM THESE STUDIES 
Tryp Plasmid name Marker 
pSk-hygro-ko-TbOrc1 Hyg 
pSK-tbTRF-5`-UTR-Phleo-Ty1-Puro-
TbTRF-3`-UTR (5) 
Phleo, Puro 
pSK-tbTRF-5`-UTR-Phleo-Ty1-Puro-
R22K-TbTRF-3`-UTR (1) 
Phleo, Puro 
pSK-tbTRF-5`-UTR-Phleo-Ty1-Puro-
R22E-TbTRF-3`-UTR (1) 
Phleo, Puro 
pSK-tbTRF-5`-UTR-Phleo-Ty1-Puro-
H70R-TbTRF-3`-UTR (1) 
Phleo, Puro 
pSK-tbTRF-5`-UTR-Phleo-Ty1-Puro-
Q44S-TbTRF-3`-UTR (1) 
Phleo, Puro 
pSK-tbTRF-5`-UTR-Phleo-Ty1-Puro-
Q45S-TbTRF-3`-UTR (2) 
Phleo, Puro 
pSK-tbTRF-5`-UTR-Phleo-Ty1-Puro-
R72K-TbTRF-3`-UTR (1) 
Phleo, Puro 
pSK-tbTRF-5`-UTR-Phleo-Ty1-Puro-
R72E-TbTRF-3`-UTR (4) 
Phleo, Puro 
pSK-tbTRF-5`-UTR-Phleo-Ty1-Puro-
R76K-TbTRF-3`-UTR (2) 
Phleo, Puro 
pSK-tbTRF-5`-UTR-Phleo-Ty1-Puro-
R76E-TbTRF-3`-UTR (8) 
Phleo, Puro 
pSk-Ty1-TbTRF-R22K-Phleo clone 1 Phleo 
pSk-Ty1-TbTRF-Q44S-Phleo clone 1 Phleo 
pSk-Ty1-TbTRF-Q45S-Phleo clone 5 Phleo 
pSk-Ty1-TbTRF-H70R-Phleo clone 1 Phleo 
pSk-Ty1-TbTRF-R72K-Phleo clone 1 Phleo 
pSk-Ty1-TbTRF-R76K-Phleo clone 1 Phleo 
pSK-Ty1-TbTRF-Phleo Clone 17 Phleo 
 
Yeast Plasmid name Yeast marker 
pACT-TbORC1 Leu2 
pBTM116-TbORC1 TRP1 
pBTM116-TbTRF-FL-R22K clone 1 TRP1 
pBTM116-TbTRF-MYB-R22K clone 1 TRP1 
pBTM116-TbTRF-FL-Q44S clone 1 TRP1 
pBTM116-TbTRF-MYB-Q44S clone 1 TRP1 
pBTM116-TbTRF-FL-Q45S clone 13 TRP1 
pBTM116-TbTRF-MYB-Q45S clone 2 TRP1 
pBTM116-TbTRF-FL-H70R clone 5 TRP1 
pBTM116-TbTRF-MYB-H70R clone 2 TRP1 
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pBTM116-TbTRF-FL-R72K clone 1 TRP1 
pBTM116-TbTRF-MYB-R72K clone 2 TRP1 
pBTM116-TbTRF-FL-R76K clone 1 TRP1 
pBTM116-TbTRF-MYB-R72K clone 5 TRP1 
 
Note: TbTRF MYB domain mutants are labeled with their corresponding position within 
the MYB domain. The following table describes the original position within TbTRF. 
 
Location of mutation in MYB domain Location of mutation in TbTRF ORF 
R22 R298 
Q44 Q320 
Q45 Q321 
H70 H346 
R72 R348 
R76 R352 
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APPENDEX D 
 
ANTIBODIES USED IN THESE STUDIES   
 
Name Usage Vendor 
Mouse-anti-LexA Western Blot, detects lexA 
fused proteins. 
Santa Cruz Biotechnology 
Mouse-anti-Gal4 Western Blot, Gal4 fused 
proteins. 
AbCam 
Mouse-HA probe Western Blot, detects F2H-
tagged proteins 
Santa Cruz 
Mouse-anti-12CA5 Western Blot, detects F2H-
tagged proteins 
MSKCC, AB core facility 
Mouse-anti-BB2 Western Blot, detects Ty1-
tagged protiens. 
MSKCC, AB core facility 
Goat-anti-EF-2 Western Blot, detects EF-2 
as a loading control. 
Santa Cruz Biotechnology 
Mouse-anti-H3 Western Blot, detects H3 as 
a loading control. 
Abcam 
Chicken-anti-protein A Western Blot, detects 
protein A in PTP tag. 
Abcam 
Mouse-TAT-1 Western Blot, detects 
tubulin as a loading control. 
Kind Gift from Keith Gull 
Rabbit-anti-VSG9 Western Blot, detects 
VSG9. 
Kind Gift from Piet Borst 
Rabbit-anti-VSG13 Western Blot, detects 
VSG9. 
Kind Gift from Piet Borst 
Rabbit-anti-TbTRF (1260) Western Blot, detects 
TbTRF. 
Lab generated 
Rabbit-anti-TbTRF (1261) Western Blot, detects 
TbTRF. 
Lab generated 
Rabbit-anti-TbRAP1 (597) Western Blot, detects 
TbRAP1. 
Lab generated 
Rabbit-anti-TbRAP1 (598) Western Blot, detects 
TbRAP1. 
Lab generated 
Alexa-488-anti-VSG3 Immunofluorescence, 
detects VSG3. 
Kind Gift from Nina 
Papavasiliou 
Alexa-647-anti-VSG13 Immunofluorescence, 
detects VSG13. 
Kind Gift from Nina 
Papavasiliou 
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APPENDEX E 
 
STRAINS GENERATED FROM THESE STUDIES 
 
Name Selection Markers 
SM-PBS-TbORC1-F2H-TbORC1 G419, Phleo, Puro 
SM-PBS- F2H-TbOrc1-skohygro-ORC1  G418, Phleo, Puro, Hyg 
SM-TbTRF-sko-hygro G418, Hyg 
SM-TbTRF-sko-ko-hygro-Ty1-TbTRF R22K  G418, Hyg, Phleo, Puro  
SM-TbTRF-sko-ko-hygro-Ty1-TbTRF H70R B1 G418, Hyg, Phleo, Puro  
SM-TbTRF-sko-ko-hygro-Ty1-TbTRF R72K B1 G418, Hyg, Phleo, Puro  
SM-TbTRF-sko-ko-hygro-Ty1-TbTRF Q44S B1 G418, Hyg, Phleo, Puro  
SM-TbTRF-sko-ko-hygro-Ty1-TbTRF R76K B1 G418, Hyg, Phleo, Puro  
SM-TbTRF-sko-ko-hygro-Ty1-TbTRF Q45S B1 G418, Hyg, Phleo, Puro  
HSTB261-TbTRF-sko-ko-hygro-Ty1-TbTRF R22K  G418, Hyg, Phleo, Puro, Bsd 
HSTB261-TbTRF-sko-ko-hygro-Ty1-TbTRF H70R G418, Hyg, Phleo, Puro, Bsd 
HSTB261-TbTRF-sko-ko-hygro-Ty1-TbTRF R72K G418, Hyg, Phleo, Puro, Bsd 
HSTB261-tbTRF-sko-ko-hygro-Ty1-tbTRF Q44S  G418, Hyg, Phleo, Puro, Bsd 
HSTB261-TbTRF-sko-ko-hygro-Ty1-TbTRF R76K G418, Hyg, Phleo, Puro, Bsd 
HSTB261-TbTRF-sko-ko-hygro-Ty1-TbTRF Q45S  G418, Hyg, Phleo, Puro, Bsd 
SM-TbTEL2-Ri1/2 G418, Phleo 
SM-TbTEL2-Ri1/2-sko-bsd G418, Phleo, Bsd 
SM-TbTEL2-Ri1/2-sko-bsd-F2H-TbTEL2 G418, Phleo, Bsd, Puro 
HSTB261- TbTEL2-Ri1/2 G418, Phleo, Bsd, Puro 
SM-TbTEL2-Ri1/2-sko-bsd-F2H-TbTOR1 G418, Phleo, Bsd, Puro 
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APPENDIX F 
ABBREVEATIONS  
 
BSD Blastisidin 
BF Blood stream Form 
ChIP Chromatin Immunoprecipitation 
CT C-terminus 
ES Expression Site 
EF-2 Elongation Factor-2 
G418 Neomycin 
GC Gene Conversion 
H3 Histone 3 
Hyg Hygromycin 
ICs Intermediate base Chromosomes 
IF Immunofluorescence 
IP Immunoprecipitation 
ITC Isothermal Titration Calorimetry 
J-base Beta-D-glucosyl-hydroxylmethyluracil 
MBCs Mega base Chromosomes 
MCs Mini base Chromosomes 
mVSGs Metacyclic form VSGs 
NT N-terminus 
ORC Origin Recognition Complex 
Phleo Phleomycin 
PFGE Pulse Field Gel Electrophoresis 
PF Procyclic Form 
Puro Puromycin 
TEL2 Telomere length regulator protein 
TOR1 Target of Rapamycin Kinase 1 
TRF TTAGGG Repeat Binding Factor 
protein 
TPE Telomere Position Effect 
UTR Un-translated Region 
VSG Variant Surface Glycoprotein 
WT Wild-type 
  
 
 
 
 
 
 
 
 
 
